FORM 10K

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of Form 10-K or any amendment to this Form 10-K. ¨

As of June 28, 2002, the aggregate market value of the registrant’s voting stock held by non-affiliates of the registrant was approximately $467,208,111 based on the closing price on that date on the New York Stock Exchange.

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes x No ¨

As of January 31, 2003, 39,725,004 shares of the registrant’s Common Stock were outstanding.

Mykrolis Corporation is a Delaware corporation organized on October 16, 2000 under the name Millipore MicroElectronics, Inc. in connection with the proposed spin-off by Millipore Corporation of its microelectronics business unit. On March 27, 2001, we changed our name to Mykrolis Corporation. On March 31, 2001, Millipore effected the separation of our business from Millipore’s business by transferring to us substantially all of the assets and liabilities associated with its microelectronics business. On August 9, 2001 we completed an initial public offering of 7,000,000 shares of our common stock, representing approximately 17.7% of the 39,500,000 total shares of the Company’s common stock outstanding. On February 27, 2002, Millipore completed the spin-off of Mykrolis by distributing to its stockholders the 32,500,000 shares of our common stock that it had held since our initial public offering. In the 1970’s and early 1980’s, Millipore internally developed products with applications in semiconductor manufacturing, which became the Millipore microelectronics business unit. Subsequently, through internal development and acquisitions, Millipore expanded that business unit into the business that now makes up Mykrolis Corporation. Unless the context otherwise requires, the terms “Mykrolis”, “we”, “our”, or the “Company” mean Mykrolis Corporation and its subsidiaries and the term “Millipore” means Millipore Corporation and its subsidiaries when referring to periods prior to March 31, 2001 and Millipore Corporation and its subsidiaries other than Mykrolis when referring to periods subsequent to March 31, 2001.

Mykrolis is a worldwide developer, manufacturer and supplier of liquid and gas delivery systems, components and consumables used to precisely measure, deliver, control and purify the process liquids, gases and chemicals, as well as the deionized water, photoresists and vacuum systems, that are used in the semiconductor manufacturing process. In addition, our products are used to manufacture a range of other products, such as flat panel displays, high purity chemicals, photoresists, solar cells, gas lasers, optical and magnetic storage devices and fiber optic cables. The Company’s products include membrane and metal based filters, housings, precision liquid dispense filtration pumps, resin based gas purifiers and mass flow and pressure controllers. The products are used by customers in manufacturing operations to remove contaminants in liquid and gas processes, to purify liquids and gases, to measure and control flow rates and to control and monitor pressure and vacuum levels during the manufacturing process. Mykrolis sells its products worldwide through a direct sales force and through distributors in selected regions.

We offer thousands of products grouped in 250 product categories, including more than 2,500 consumable products. Our consumable products are used by our customers in the manufacturing process and require periodic replacement to maintain the purity and precision of the manufacturing process. Our products use purification technologies to remove particles, ions and molecules from liquid and gas streams. Our component and subsystem products use electro-mechanical, pressure differential and related technologies, to permit semiconductor and other electronics manufacturers to monitor and control the flow and condition of liquids, gases and vacuum systems used in these manufacturing processes. Our specially designed proprietary filters remove sub-micron sized particles and bubbles from the different chemical fluid streams, typically liquid or gas, that are used in the manufacturing process.

The Company operates in one reportable business segment: the development, manufacture and sale of consumable purification products and capital equipment to semiconductor fabrication companies and other companies using similar manufacturing processes, as well as to OEM suppliers to those companies. The Company also provides capital equipment warranty and repair services to customers in this segment. In 2002, 2001 and 2000 approximately 69%, 67% and 61%, respectively, of our net sales were made to customers outside the Americas. Industry and geographic segment information is discussed in Note 13 to the Mykrolis Corporation Consolidated and Combined Financial Statements (the “Financial Statements”) included in Item 8 below, which Note is hereby incorporated herein by reference.

Our products include equipment and consumable products used in the manufacture of semiconductors and other electronic devices. Our equipment products comprise components and subsystems used to monitor and control the delivery of process liquids and gases that are used in the semiconductor manufacturing process. Our consumable products comprise liquid filters and gas filters and purifiers, which purify the process fluids used in the semiconductor manufacturing process. Equipment accounted for 35%, 42% and 50% of our net sales for the years ended December 31, 2002, 2001 and 2000, respectively, and consumable products accounted for, 65%, 58% and 50%, respectively, of our net sales in these same periods. In each of these periods photochemical dispense systems and gas flow measurement and control products each accounted for approximately 30% of our net sales from equipment, and liquid filtration and purification products accounted for more than two-thirds of our net sales from consumable products. In each of our last three fiscal years, our sales of pressure measurement and control products, vacuum gauges, valves and controllers and our sales outside of the semiconductor industry have each accounted for less than 10% of our net sales in such periods. Our two product classes include the following specific product types:

Based upon our proprietary integrated, high precision photochemical filtration and dispense systems that utilize patented two-stage technology, we believe that we are the only supplier to the microelectronics industry with integrated filtration and dispense technology. Our proprietary technology also includes our Connectology^™ technology, low hold-up volume disposable filters, hollow fiber membrane technology and patented digital valve control technology. Two-stage technology, as opposed to conventional single-stage technology, allows for filtering and dispensing of photochemicals at different rates, reducing defects in wafers. Connectology technology allows for filter changes in less than two minutes, faster than our conventional filters and with less potential exposure to hazardous chemicals. Low hold-up volume disposable filters reduce the amount of expensive chemicals lost each time a filter is changed. Hollow fiber membrane technology allows the process liquids and gases to flow through the hollow center of a straw-like tube made of a porous membrane material. Digital valve control technology improves chemical uniformity on wafers and improves ease of operation in the fabrication plant. In addition, high precision liquid dispense systems based on our proprietary patented technology enable uniform application of photoresists for the spin-coating process where uniformity is measured in units of Angstroms, a fraction of the thickness of a human hair.

We offer a complete product family of digital and analog mass flow controllers to meet the stringent requirements of semiconductor processing. Mass flow controllers are devices that automatically and precisely measure and control the flow rates of multiple liquids and gases into the process chamber in order to maintain circuit quality, reduce maintenance requirements and prolong the life of the equipment used in the manufacturing process. We have also developed pressure-based mass flow controllers, which measure and control the liquids and gases by controlling the pressure applied to these fluids. Our IntelliFlow^™ product platform combines our gas measurement and control products with the DeviceNet^™ communications protocol to provide a digital solution to achieve advanced process control and network communications. The embedded diagnostics software provides real time feedback as to gas measurement and control performance thereby minimizing costly unscheduled down time.

We offer a wide variety of pressure measurement and control products to meet the needs of our customers, including pressure gauges, transducers, displays and scales. These products offer high rates of accuracy, reliability, repeatability and purity. Transducers measure the pressure applied to the wafer and the fluids during the manufacturing process. Our displays range from local readout displays at the point-of-use to real-time displays at the point-of-source. Our scales are used to provide real-time volume measurement.

We offer a wide range of vacuum instruments consisting of vacuum measurement sensors and associated power supplies and display units. Our vacuum valves are used between the process chamber and the pump that delivers the gas to the process chamber and can withstand temperatures of 150 degrees Celsius. These vacuum gauges directly measure the level of pressure in the process chamber and between the process chamber and a pump. These gauges can measure pressures as low as 0.1 Torr, which is a fraction of the Earth’s atmospheric pressure. We also manufacture a range of vacuum controllers that take the signals from the vacuum gauges and provide the necessary control signals to the vacuum valves in order to maintain precise processing parameters.

Liquid processing includes such steps as photolithography, deposition, planarization and surface etching and cleaning. The fluids that are used include various mixtures of acids, bases, solvents, slurries and photochemicals, which in turn are used over a broad range of operating conditions, including temperatures from 5 degrees Celsius up to 180 degrees Celsius. Specially designed proprietary filters remove sub-micron sized particles and bubbles from the different fluid streams that are used in the manufacturing process. Some of our filters are constructed with ultra-high molecular weight polyethylene hollow fiber membranes that offer improved bubble clearance and gel removal, either of which can cause defects in the wafers if not removed. These filters also utilize patented Connectology^™ technology to provide for rapid filter changes, minimal equipment downtime and limited operator exposure to toxic chemicals.

Our Wafergard^®, ChamberGard^™ and Waferpure^® particle and molecular filtration and purification products provide for the distribution of gas in the process chamber in order to eliminate system and wafer problems due to particulate, atmospheric and chemical contaminants. These filters are able to retain all particles 0.003 microns and larger. Our metal filters, such as stainless steel and nickel filters, reduce outgassing and improve corrosion resistance. Our Waferpure purifiers chemically react with and absorb volatile contaminants, such as oxygen and water, to prevent contamination and our ChamberGard vent diffusers reduce particle contamination and processing cycle times.

We provide strong technical support to our customers through local service groups and engineers consisting of field applications engineers, technical service groups, applications development groups and training departments. Our field applications engineers, located in the United States and in eight other countries, work directly with our customers on product qualification and process improvement in their facilities. In addition, in response to customer needs for local technical service and fast turn-around time, we maintain regional applications laboratories. Our applications laboratories maintain process equipment that simulate customers’ applications and industry test standards and provide product evaluation, technical support and complaint resolution for our customers. Our service centers are responsible for calibration, repairs and servicing of our products. These service centers also support industry collaborations and provide additional technical expertise to our customers. We maintain thirteen service centers located in California, Texas, Japan, Korea, China, Taiwan, Singapore, Germany, France and the United Kingdom.

Our major customer groups include integrated circuit manufacturers, original equipment manufacturers that provide equipment to integrated circuit manufacturers, and gas and chemical manufacturing companies.

The increasing complexity of semiconductor devices has resulted in the need for more complex, higher-precision liquid and gas delivery, measurement, control and purification systems. The ability of semiconductor device manufacturers to offer integrated circuits with smaller geometries, greater functionality and higher performance at a lower cost requires continuous improvements in semiconductor process equipment, process controls and liquid and gas delivery systems. Manufacturing a semiconductor can require hundreds of process steps, many of which involve the precise measurement, delivery, control and purification of process liquids, gases and other chemicals. The design and performance of those liquid and gas delivery systems, subsystems, components and consumables are critical to the semiconductor manufacturing process because they directly affect cost of ownership and manufacturing yield.

As equipment and process complexity in semiconductor manufacturing increases, semiconductor original equipment manufacturers and device manufacturers are seeking to improve time-to-market, reduce manufacturing costs and improve production quality and reliability and long-term service and support. To address these issues, semiconductor equipment companies and device manufacturers are outsourcing the design and manufacture of liquid and gas delivery, measurement, control and purification systems, components, and consumables to us and to other well-established subsystem and component companies that have worldwide presence and leading technologies.

The manufacturing of semiconductors and other electronic devices can require hundreds of process steps. These steps take place within a process chamber, which provides a controlled environment for the fabrication of semiconductor and other electronic devices. The primary processing steps in the manufacture of semiconductors are listed below; the Company offers products used in each of these process steps.

Deposition. Deposition refers to placing layers of insulating or conductive materials on a wafer surface in thin films that make up the circuit elements of semiconductor devices. The two main deposition processes are physical vapor deposition, where a thin film is deposited on a wafer surface in a low-pressure gas environment, and chemical vapor deposition, where a thin film is deposited on a wafer surface using a gas medium and a chemical bonding process. In addition, electro-plating technology is utilized for the deposition of low resistance materials such as copper. The control of uniformity and thickness of these films through filtration and purification of the fluids and materials used during the process is critical to the performance of the semiconductor circuit and, consequently, the manufacturing yield.

Chemical Mechanical Planarization. Chemical mechanical planarization flattens, or planarizes, the topography of the film surface to permit the patterning of small features on the resulting smooth surface by the photolithography process. Semiconductor manufacturers need filtration and purification systems to maintain acceptable manufacturing yields through the chemical mechanical planarization process by filtering the liquid slurries, which are solutions containing abrasive particles in a chemical mixture, to remove oversized particles and contaminants that can cause defects on a wafer’s surface while not affecting the functioning of the abrasive particles in the liquid slurries.

Photolithography. Photolithography is the process step that defines the patterns of the circuits to be built on the chip. Before photolithography, a wafer is pre-coated with photoresist, a light sensitive film composed of ultra-high purity chemicals in liquid form. The photoresist is exposed to specific forms of radiation, such as ultraviolet light, electrons or x-rays, to form patterns which eventually become the circuitry on the chip. This process is repeated many times, using different patterns and interconnects between layers to form the complex, multi-layer circuitry on a semiconductor chip. As device geometries decrease and wafer sizes increase, it is even more critical that these photoresists have an accurate thickness and uniformity, as well as low levels of contamination, for manufacturers to achieve acceptable yields in the manufacturing process.

Etch and Resist Strip. Etch is the process of selectively removing precise areas of thin films that have been deposited on the surface of a wafer. The hardened photoresist protects the remaining material that makes up the circuits. During etch, specific areas of the film not covered by photoresist are removed to leave a desired circuit

pattern. Similarly, resist strip is a process of removing the photoresist material from the wafer after the desired pattern has been placed on the wafer. Emerging advanced etch and resist strip applications require precisely controlled gas chemistries and flow rates in order to achieve precise etch and resist strip characteristics.

Wet Cleaning. Ultra-high purity chemicals and photoresists of precise composition are used to clean the wafers, to pattern circuit images and to remove photoresists after etch. Before processes such as photoresist coating, thin film deposition, ion implantation, diffusion and oxidation, and after processes, such as ion implantation and etch, the photoresists must be stripped off, and the wafer cleaned in multiple steps of chemical processes. To maintain manufacturing yields and avoid defective products, these chemicals must be maintained at very high purity levels without the presence of foreign material such as particles, ions or organic contaminants.

Many of the processes used to manufacture semiconductors are also used to manufacture flat panel displays, magnetic and optical storage devices and fiber optic cables for telecommunications, resulting in the need for similar filtration, purification, control and measurement capabilities.

Our most significant customers based on sales in 2002 include industry leaders, such as Applied Materials, Inc., Dainippon Screen Manufacturing Co., Ltd., UMC Group Samsung Electronics Co., Ltd., Taiwan Semiconductor Manufacturing Co. Ltd. and Tokyo Electron Limited. We also sell our products to flat panel display original equipment manufacturers, materials suppliers and end-users. The major manufacturers for flat panel displays and flat panel display equipment are concentrated in Japan, Korea and other parts of Asia.

In 2002, 2001 and 2000, sales to our top ten customers accounted for approximately 35%, 33% and 39%, respectively, of our net sales. During those same periods, Tokyo Electron Limited accounted for approximately 13%, 14% and 18%, respectively, of our net sales and international net sales represented approximately 69%, 67% and 61%, respectively, of our net sales. Over 3,000 customers purchased products from us during 2002.

We may enter into supply agreements with our customers to govern the conduct of business between us and our customers, including the manufacture of our products. These agreements generally have a term of one to three years but these agreements do not contain any long-term purchase orders or commitments. Instead, we work closely with our customers to develop non-binding forecasts of the future volume of orders. However, customers may cancel their orders, change production quantities from forecasted volumes or delay production for a number of reasons beyond our control.

We sell our products worldwide primarily through our own direct sales force located in nine offices in major industrialized and developed countries, as well as through independent distributors in other parts of the world. As of December 31, 2002, our sales and marketing force consisted of approximately 188 employees worldwide. Our direct sales force is supplemented by independent sales representatives and agents.

Our marketing efforts focus on our “push/pull” marketing strategy in order to maximize our selling opportunities. We work with original equipment manufacturers to design tools that require our products and we create end user “pull” demand where the products are specified by the semiconductor manufacturers. Our industry relationships have provided us with the opportunity for significant collaboration with our customers at the product design stage that has facilitated our ability to introduce new products and applications that meet our customers’ needs. In addition, we are constantly identifying for our customers the variety of analytical, purification and process control challenges which may be addressed by our products. Further, we adapt our products and technologies to process control issues identified by our customers. Our sales representatives provide our customers with worldwide support and information on our products.

We believe that our technical support services are important to our marketing efforts. These services include assisting in defining a customer’s needs, evaluating alternative products, designing a specific system to perform

the desired separation, training users and assisting customers in compliance with relevant government regulations. In addition, we maintain a network of service centers located in the United States and in key international markets to support our products.

The market for our products is highly competitive. While price is an important factor, we compete primarily on the basis of the following factors:

We believe that we compete favorably with respect to all of the factors listed above, but we cannot assure you that we will continue to do so. We believe that our key competitive strengths include our broad product line, the low total cost of ownership of our products, our ability to provide our consumables customers with quick order fulfillment and our technical expertise. However, our competitive position varies depending on the market segment and specific product areas within these segments. For example, in the market for photochemical dispense systems, we believe that our patented technology, our longstanding relationships with leading original equipment manufacturers in this market niche and our ability to support our customers’ needs on a global basis have allowed us to compete favorably. In contrast, other companies have more established positions in the markets related to gas delivery systems and components, such as gas flow measurement and control products, pressure measurement and control products and vacuum gauges, valves and controllers. While we have longstanding relationships with a number of semiconductor and other electronic device manufacturers, we also face significant competition from companies that have longstanding relationships with other semiconductor and electronic device manufacturers and, as a result, have been able to have their products specified by those customers for use in manufacturers’ fabrication facilities. In addition, some of our competitors have cost advantages over us in the markets for gas delivery systems and components due to their larger market share and the related economies of scale. In the markets for our consumable products, we believe that our differentiated membrane technology, strong supply chain capabilities, which allow us to provide our customers with quick order fulfillment, and technical expertise, which enables us to develop membranes to meet specific customer needs and assist our customers in improving the functionality of our membranes for particular applications, allow us to compete favorably. In these markets our competitors compete against us on the basis of price, as well as alternative membrane technology having different functionality, manufacturing capabilities and breadth of geographic presence.

The market for our products is highly fragmented, and we compete with a number of different companies, including Iwaki Co., Ltd., MKS Instruments, Inc., Advanced Energy Industries Inc., Mott Metallurgical Corporation and Pall Corporation. Some of our competitors are larger and have greater resources than we do. In some cases, our competitors are smaller than us, but well-established in specific product niches. However, we believe that none of our competitors competes with us across all of our product offerings and that, within the markets that we serve, we offer a broader line of products, make use of a wider range of process control technologies and address a broader range of applications than any single competitor. Nonetheless, competitors with greater financial resources may be able to offer lower prices, additional products or services or other incentives that we cannot match or offer. These competitors may be in a stronger position to respond quickly to new technologies, devote more resources to developing new technologies and may be able to undertake more extensive marketing campaigns. They also may adopt more aggressive pricing policies and make more attractive offers to potential customers, employees and strategic partners.

Semiconductor and other electronic device manufacturers may direct semiconductor capital equipment manufacturers to use a specified supplier’s product in their equipment. Accordingly, our success depends in part on our ability to have semiconductor and other electronic device manufacturers specify that our products be used at their fabrication facilities. Some of our competitors may have more developed relationships with semiconductor and other electronic device manufacturers, which enables them to have their products specified for use in manufacturers’ fabrication facilities.

Our aggregate research and development expenses in 2002, 2001 and 2000 were $19.7 million, $19.8 million, and $23.2 million, respectively. As of December 31, 2002, we had approximately 101 employees in engineering, research and development. In addition, we have followed a practice of supplementing our internal research and development efforts by licensing technology from unaffiliated third parties and/or acquiring distribution rights with respect thereto when we believe it is in our long-term interests to do so.

To meet the global needs of our customers, we have research and development capabilities in the United States and Japan. Our research and development efforts are directed toward developing and improving our technology platforms for semiconductor and advanced processing applications and identifying and developing products for new applications for which fluid management plays a critical role. Recently, our efforts have been particularly focused on the development of new materials and technology associated with key industry trends, such as the transition from the use of 200 millimeter wafers to 300 millimeter wafers, the shrinking of integrated circuit line-widths and the use of new classes of materials, such as copper, titanium nitride and organic and inorganic dielectric materials. We have undertaken an initiative to involve our marketing, engineering, manufacturing and sales personnel in the development of new products in order to reduce the time to market for new products. Our employees also work closely with our customers’ development personnel. These relationships help us identify and define future technical needs on which to focus our research and development efforts. In addition, we participate in Semiconductor Equipment and Materials International (SEMI), a consortium of semiconductor equipment suppliers. We also support research at academic and other institutions targeted at advances in materials science and semiconductor process development.

On the effective date of our separation from Millipore, key membrane researchers and engineers were transferred to us. In addition, we entered into a five-year contractual research agreement with Millipore to minimize the interruption of our long-term research projects and transfer to us full ownership of specified related intellectual property rights.

We rely on a combination of patent, copyright, trademark and trade secret laws and license agreements to establish and protect our proprietary rights. We maintain 95 issued and enforceable U.S. patents, 125 issued and enforceable foreign patents, including counterparts to U.S. filings, 81 pending U.S. patent applications, 21 pending filings under the Patent Cooperation Treaty not yet nationalized and 240 pending foreign patent applications. While we believe that patents may be important for aspects of our business, such as our patents related to photoresist dispense pumps, polymer membranes, gas filters, gas and liquid contactors, fluid control processes, mass flow controllers and our Connectology^™ products, which U.S. patents expire between 2005 and 2021, we believe that our success depends more upon close customer contact, innovation, technological expertise, responsiveness and worldwide distribution. Additionally, while our patented technology may delay or deter a competitor in offering a competing product, we do not believe that our patent portfolio functions as a barrier to entry for any of our competitors. In addition, while we license and will continue to license technology used in the manufacture and distribution of products from third parties, except as described in the “Risks Related to our Separation from Millipore” section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Item 7 below, which information is hereby incorporated by reference, these licenses are not currently related to any of our core product technologies.

We require each of our employees, including our executive officers, to enter into standard agreements pursuant to which the employee agrees to keep confidential all of our proprietary information and to assign to us all inventions made while employed by us.

A number of our patented products were specifically developed in response to the transition from 200 millimeter wafers to 300 millimeter wafers, and many of our new products are specifically targeted to meet the more stringent requirements for the advanced technologies dominating 300 millimeter wafer manufacturing processes. Examples include our Solaris^™ chemical mechanical planarization filters for copper slurries, IntelliGen^™ photoresist dispense pumps with digital valves targeted for photolithography applications and our Intelliflow^™ mass flow controllers for 300 millimeter tool automation.

In connection with our separation from Millipore, we were assigned patents and trademarks which relate exclusively to our business. Patented technology that is used by both Millipore and Mykrolis was generally retained by Millipore and licensed to us with exclusive rights in our fields of use that are generally defined by the operating scope of our business at the time of our separation from Millipore. In some cases, the technology was transferred to us, and we granted Millipore an exclusive license in its fields of use in the biopharmaceutical and related industries. These licenses are assignable by the licensee only in connection with a sale of its business, do not require the payment of any license fees or royalties by either Millipore or us and will continue in effect for the life of the patents. In addition, in order to assure future access to patented technology not licensed as part of the separation, the separation agreements provide each of us with a technology license option. The option grants each party a five-year option to acquire a royalty bearing license to patented technology existing as of the separation date that is owned by the other party and is not currently used by the optionee but may be useful for future products, with exclusive rights in its fields of use. The license term would extend for the life of the subject patents.

Our operations are subject to federal, state and local regulatory requirements relating to environmental, waste management and health and safety matters, including measures relating to the release, use, storage, treatment, transportation, discharge, disposal and remediation of contaminants, hazardous substances and wastes, as well as practices and procedures applicable to the construction and operation of our plants. There can be no assurance that we will not incur material costs and liabilities or that our past or future operations will not result in exposure to injury or claims of injury by employees or the public. Although some risk of costs and liabilities related to these matters is inherent in our business, as with many similar businesses, we believe that our business is operated in substantial compliance with applicable regulations. However, new, modified or more stringent requirements or enforcement policies could be adopted, which could adversely affect us. While we expect that capital expenditures will be necessary to assure that any new manufacturing facility is in compliance with environmental and health and safety laws, we do not expect these expenditures to be material. Otherwise, we are not presently aware of any facts or circumstances that would cause us to incur significant liabilities in the future related to environmental, health and safety law compliance.

As of February 1, 2003, we had approximately 903 full-time employees, including approximately 101 in engineering, research and development and approximately 188 in sales and marketing. Given the variability of business cycles in the semiconductor industry and the quick response time required by our customers, it is critical that we be able to quickly adjust the size of our production staff to maximize efficiency. Therefore, we use skilled temporary labor as required. In connection with our separation from Millipore, we hired personnel to facilitate our operation as an independent company and in replacement of services formerly provided by Millipore’s central functions.

None of our employees are represented by a labor union or covered by a collective bargaining agreement other than statutorily mandated programs in European countries.

In March of 2001, the Board of Directors of Mykrolis adopted a shareholder rights plan (the “Rights Plan”) pursuant to which Mykrolis declared a dividend on November 29, 2001 to its shareholders of record on December 31, 2001 of the right to purchase (a “Right”) one additional share of Mykrolis Common Stock for each share of Mykrolis Common Stock owned, at a price of $130.00 for each share. The Rights Plan is designed to protect Mykrolis’ shareholders from attempts by others to acquire Mykrolis on terms or by using tactics that could deny all shareholders the opportunity to realize the full value of their investment. The Rights are attached to the shares of our common stock until certain triggering events occur. The Rights authorize the holders to purchase shares of our common stock at a 50% discount from market value upon the occurrence of specified triggering events, including, unless approved by our board of directors, an acquisition by a person or group of specified levels of beneficial ownership of our common stock or a tender offer for our common stock. The common stock purchase rights are redeemable by us for $0.01 and will expire in March of 2011. One of the events which will trigger the common stock purchase rights is the acquisition, or commencement of a tender offer, by a person (an Acquiring Person, as defined in the shareholder rights plan), other than Mykrolis or any of our subsidiaries or employee benefit plans, of 15% or more of the outstanding shares of our common stock. An Acquiring Person may not exercise a common stock purchase right.

Mykrolis’ products are made from a wide variety of raw materials which are generally available in quantity from alternate sources of supply. Accordingly, as a general matter, Mykrolis is not substantially dependent upon any single supplier.

The following is a list, as of February 1, 2003, of the Executive Officers of Mykrolis. All of the officers of Mykrolis Corporation listed below were elected to serve until the first Directors Meeting following the 2003 Annual Stockholders Meeting.

C. William Zadel has been our Chairman and Chief Executive Officer since November 2000 and one of our directors since February 2001. Mr. Zadel was Chief Executive Officer, Chairman and President of Millipore from February 1996 through April 2001, at which time he resigned as President but continued as Chief Executive Officer until August 2001. Mr. Zadel continued to serve Millipore as a non-executive Chairman of the Board and a director until April 2002. Mr. Zadel had been, since 1986, President and Chief Executive Officer of Ciba Corning Diagnostics Corp., a company that develops, manufactures and sells medical diagnostic products. Prior to that he was Senior Vice President of Corning Glass Works (now Corning Inc.) Americas Operations since 1985 and Vice President of business development since 1983. Mr. Zadel currently serves on the Boards of Directors of Kulicke and Soffa Industries, Inc. and Matritech, Inc. Mr. Zadel is a Director (Chairman 1999 – 2001) of the Massachusetts High Technology Council. He has also served as the Chairman of the Health Industry Manufacturers Association from 1994 to 1995.

Jean-Marc Pandraud has been our President and Chief Operating Officer since January 2001. Prior to that he served as Vice President and General Manager of the Microelectronics Divisions of Millipore, a position he had held since July 1999. From 1994 until 1999, Mr. Pandraud served as the Vice President and General Manager of Millipore’s Laboratory Water Division and was also Regional Manager of Millipore’s Latin American operations from 1997 until 1999. Mr. Pandraud also served as the Managing Director of Millipore’s French subsidiary and as European General Manager for the Millipore Analytical Division from 1988 until 1994.

Bertrand Loy has been our Vice President and Chief Financial Officer since January 2001. Prior to that, Mr. Loy served as the Chief Information Officer of Millipore from April 1999 until December 2000. From 1995 until 1999, he served as the Division Controller for Millipore’s Laboratory Water Division. From 1989 until 1995, Mr. Loy served Sandoz Pharmaceuticals (now Novartis) in a variety of financial, audit and controller positions located in Europe, Central America and Japan.

Peter W. Walcott has been our Vice President, Secretary and General Counsel since October 2000. Mr. Walcott served as the Assistant General Counsel of Millipore from 1981 until March 2001.

Fred E. Faulkner, Jr. has been our Vice President—Worldwide Manufacturing since April 2001. Prior to joining Mykrolis, Mr. Faulkner served as Millipore’s Director of Manufacturing Operations from May 2000 until April 2001. Prior to that, Mr. Faulkner was President and Chief Operating Officer of Boston Acoustics, Inc., a designer and manufacturer of high-performance audio systems, from April 1997 until April 2000. Before joining Boston Acoustics, Mr. Faulkner served as Vice President of Technical Operations for Millipore’s microelectronics division from June 1994 until April 1997.

Takashi Mizuno has been our Vice President since April 2001 and has been President of our Japanese subsidiary, Nihon Mykrolis KK since April 2001. Mr. Mizuno was a Director of Global Accounts for Tokyo Electron Limited from February 2000 until April 2001. Prior to that, Mr. Mizuno served as Millipore’s Director of Laboratory Research from September 1995 until February 2000 and as Division Manager of Millipore’s Laboratory Water division from January 1995 until September 1995.

Robert Crook has been our Vice President—Human Resources since April 2001. Prior to that, Mr. Crook served as Millipore’s Human Resources Manager from November 1999 until April 2001. Before joining Millipore, Mr. Crook served as Vice President of Human Resources for the Transnational Group, a marketing and financial services company from October 1996 until November 1999. Before that Mr. Crook served as a Human Resources Manager for Digital Equipment Corporation.

Gerry Mackay has been our Vice President—Worldwide Sales & Marketing since February 2002. Prior to joining Mykrolis, Mr. Mackay served Millipore in various sales and marketing capacities since August of 1987, first with Millipore’s UK subsidiary and subsequently as the General Manager for Millipore’s Asia operations and finally as Worldwide Director of Marketing—Biotechnology. Mr. Mackay was designated as an Executive Officer by our Board of Directors in April 2002.

Jieh-Hwa Shyu has been our Vice President—R & D since April of 2001 and was designated as an Executive Officer by our Board of Directors in April 2002. Prior to our separation from Millipore, Mr. Shyu served the Microelectronic Division of Millipore as a Director of R & D from 1997 until March 2001. Prior to joining Millipore, Mr. Shyu served Digital Equipment Corporation as a Principal Engineer and Supervisor.

Our Annual Report on Form 10-K, our quarterly reports on Form 10-Q and any current reports on Form 8-K that we may file as well as any amendments to any of those reports are available free of charge on or through our website as soon as reasonably practicable after we file them electronically with the S.E.C. Our website is located at http://www.Mykrolis.com; these reports can be found under the “Investor Relations” menu — SEC Filings.

Our principal executive offices are located in Billerica, Massachusetts. We also have manufacturing and design facilities in the United States and Japan. Information about these facilities is set forth below:

In addition, we lease a 144,000 square foot building in Bedford, Massachusetts of which 70,000 square feet is subleased by us to a third party under a sublease expiring in 2005. We have an option to purchase this leased facility at fair market value between June 2005 and November 2005, the expiration date of our lease, and our landlord has an option to sell us this facility at 90% of its fair market value prior to November 30, 2005. If our landlord exercises the option to sell, we will have one year to complete the purchase of the facility, during which time interest on the purchase price will accrue. Since this facility was deemed to be inappropriate for our business needs, we closed this facility during the third quarter of 2001. We are currently attempting to sublease this facility.

We lease approximately 4,200 square feet of manufacturing space in Millipore’s facility located at 80 Ashby Road, Bedford, MA under a transitional services agreement that expires March 31, 2006. We also lease a 7,000 square foot manufacturing facility in San Clemente, California. During the fourth quarter of 2002 we decided to close this facility; we expect this closure to be completed during the third quarter of 2003. The lease for this facility expires in October 2003.

We maintain a worldwide network of sales and service centers, including two in the United States, three in Europe (one in Germany, one in France and one in the United Kingdom), two in Japan and four in other parts of Asia (Taiwan, Singapore, Shanghai, PRC and Korea). Leases for our facilities expire between February 2003 and March 2014. We currently expect to be able to extend the terms of expiring leases or to find suitable replacement facilities on reasonable terms.

We believe that our facilities are well-maintained and, except as described above, suitable for their respective operations.

In addition to the above facilities that we use or have used in our operations, we continue to be a named lessee on two leases relating to facilities located in California which were formerly used by Tylan General, Inc. prior to its acquisition by Millipore in 1997. These leases expire in 2005 and 2006. These lease obligations were assumed by us pursuant to our separation from Millipore. While both of these facilities have been subleased for the remainder of their terms, under the provisions of the sublease arrangements we were not released from the lease obligations by the landlord.

We are party to lawsuits arising in the ordinary course of business. We do not believe that these proceedings individually or in the aggregate will have a material adverse effect on our financial condition, results of operations or cash flows.

Item 5. Market for Mykrolis’ Common Stock, and Related Stockholder Matters.

Mykrolis’ Common Stock, $0.01 par value, is listed on the New York Stock Exchange and is traded under the symbol “MYK”. The following table sets forth, for the indicated fiscal periods, the high and low sales prices of Mykrolis’ Common Stock (as reported on the New York Stock Exchange Composite Tape). No cash dividends have been declared (on a per share basis). On November 29, 2001 the Mykrolis Board of Directors declared a dividend of one common stock purchase right for each share of Mykrolis Common Stock outstanding to shareholders of record on December 31, 2001, payable on January 4, 2002. For a description of the Common Stock Rights Plan see “Other Information” in Item 1 above. Each right entitles the holder to purchase one share of Mykrolis Corporation Common Stock at a price of $130. As of February 1, 2003 there were approximately 2,313 shareholders of record.

The following table sets forth selected historical financial information derived from our audited consolidated and combined balance sheets and statements of operations as of and for the years ended December 31, 2002, 2001, 2000, 1999 and 1998. Our combined financial statements for periods prior to March 31, 2001 include amounts that have been derived from the consolidated financial statements and accounting records of Millipore using the historical results of operations and historical basis of assets and liabilities of our business. The selected historical financial information includes allocations of Millipore corporate expenses related to our business, including centralized research and development, legal, accounting, employee benefits, officers’ salaries, real estate, insurance, information technology services, distribution, treasury and other Millipore corporate and infrastructure costs. These expense allocations have been determined on a basis that Millipore and we consider to be a reasonable reflection of the utilization of services provided or the benefit received by us. However, the consolidated and combined financial information included herein may not necessarily reflect our operating results, financial position and cash flows in the future or what they would have been had we been a separate, stand-alone entity during all periods presented.

You should read our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated and combined financial statements and related notes included elsewhere in this document for a further explanation of the financial data summarized here.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations with the consolidated and combined financial statements and the accompanying notes to the consolidated and combined financial statements included elsewhere in this document. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risks Relating to Our Business and Industry” section of this Item 7. Our actual results may differ materially from those contained in any forward-looking statements.

We are a worldwide developer, manufacturer and supplier of liquid and gas delivery systems, components and consumables used to precisely measure, deliver, control and purify the process liquids, gases and chemicals, as well as the deionized water, photoresists and vacuum systems, that are utilized in the semiconductor manufacturing process. Our products include membrane and metal-based filters, housings, precision liquid dispense filtration pumps, resin-based gas purifiers and mass flow and pressure controllers. Our products are used by our customers in manufacturing operations to remove contaminants in liquid and gas processes, to purify liquids and gases, to measure and control flow rates and to control and monitor pressure and vacuum levels during the manufacturing process.

Our products are sold globally through a direct sales force and through distributors in selected regions. Our customers are located worldwide and we currently manufacture our products at four sites located in the United States and Japan. In 2002, as part of our separation plan from Millipore Corporation (“Millipore”), we opened a new corporate headquarters, R & D and manufacturing facility in Billerica, Massachusetts and exited the Jaffrey, New Hampshire manufacturing facility owned by Millipore.

On October 3, 2000, Millipore announced its plan to spin-off its microelectronics business which served the semiconductor industry and certain related industries with products needed to manufacture semiconductor devices as well as a range of other products that now comprises Mykrolis Corporation (“the Company”). On October 16, 2000, the Company was incorporated in Delaware as a wholly-owned subsidiary of Millipore to receive Millipore’s microelectronics business and to be the spun off company. Prior to March 2001, our business was operated as a fully integrated business unit of Millipore. On March 31, 2001, Millipore transferred to us substantially all of the assets and liabilities associated with its microelectronics business (the “Separation”). We completed our initial public offering (“IPO”) of 7 million shares of common stock on August 9, 2001 receiving net proceeds of approximately $94.0 million, after deducting underwriting commissions and offering expenses. We retained approximately $75.0 million of the net proceeds and paid the balance to Millipore as repayment of amounts outstanding as intercompany loans incurred by us in connection with the Separation. After the initial public offering, Millipore owned 32.5 million shares, or approximately 82.3%, of our total outstanding common stock. On February 27, 2002 (the “Distribution Date”), Millipore completed the spin-off of Mykrolis through the distribution to its shareholders of all of the 32.5 million shares of Mykrolis common stock owned by Millipore on that date. Mykrolis is now a fully independent company with 39.7 million shares outstanding at December 31, 2002.

In connection with our separation from Millipore, we entered into agreements with Millipore under which Millipore agreed to provide services to us during a transition period after the Separation date. The agreements related to facilities services, information technology services, distribution, accounting, finance and other services and arrangements. Under these agreements, we reimburse Millipore for the cost of these services. The duration of each of the different transition service agreements varied depending on the anticipated time it would take for us to replace the service, but was generally for a one-year period. No agreement has been extended beyond the mutually agreed upon initial transition period, with the exception of the accounting and distribution services in

Europe which was extended by one additional quarter until the end of the second quarter 2002. As most of these transition service agreements have expired without renewal, we have been able to provide these services ourselves or negotiate new agreements with various third parties as a separate stand-alone entity. We have been able to do this at costs at least as favorable as those paid to Millipore for these services. We will be terminating the use of Millipore’s Information Technology (“IT”) Data Center, which is currently hosting our IT system operations, during the first half of 2003 in accordance with the schedule contemplated by our transition service agreement. In addition, we have entered into agreements with Millipore for membrane manufacturing and supply, research and development, product distribution and contract manufacturing, generally for a five-year period. The foregoing transition agreements do not necessarily reflect the costs of obtaining the services from unrelated third parties or of our providing the applicable services ourselves. However, we believe that purchasing these products and services from Millipore provides us with an efficient means of obtaining these products and services during the transition period. In addition, we have agreed to provide transition services to Millipore, for which we are reimbursed at our cost.

Our combined financial statements for periods prior to March 31, 2001 include amounts that have been derived from the consolidated financial statements and accounting records of Millipore using the historical results of operations and historical basis of assets and liabilities of our business. We believe the assumptions underlying the combined financial statements are reasonable. However, the combined financial information included herein may not necessarily reflect our operating results, financial position and cash flows in the future or what they would have been had we been a separate, stand-alone entity during the periods presented. Because a direct ownership relationship did not exist among all our various units, Millipore’s net investment in us is shown in lieu of shareholders’ equity in the combined financial statements prior to the Separation. We began accumulating retained earnings (accumulated deficit) on April 1, 2001, following the effective date of the separation agreement with Millipore, pursuant to which our assets and liabilities were transferred to us. Beginning April 1, 2001, our consolidated financial statements include all our wholly-owned subsidiaries and our assets and liabilities. All material intercompany transactions and balances between and among our subsidiaries have been eliminated.

Prior to March 31, 2001 Millipore allocated certain corporate expenses, including centralized research and development, legal, accounting, employee benefits, officers’ salaries, facilities, insurance, information technology services, distribution, treasury and other Millipore corporate and infrastructure costs. These expense allocations were determined on a basis that Millipore and we consider to be a reasonable assessment of the utilization of services provided or the benefit received by us. At the time of Separation from Millipore, we entered into transition service agreements with Millipore for Millipore to provide specified functions and for us to reimburse Millipore for the cost of these functions. These agreements do not necessarily reflect the costs of obtaining the services from unrelated third parties or of our providing the applicable services ourselves. However, we believe that purchasing these services from Millipore provided us with an efficient means of obtaining these services during the transition period. In 2002, we purchased $7.6 million of services from Millipore under these transition services agreement. In 2001, we purchased services of $8.0 million and were allocated costs from Millipore of $10.3 million. In 2000, we were allocated $42.1 million of costs from Millipore.

Allocated costs and purchased services included in the accompanying consolidated and combined statements of operations are as follows:

In addition, we have agreed to provide transition services to Millipore, for which we are reimbursed at our cost. These amounts totaled $1.8 million and $1.7 million in 2002 and 2001 respectively, related to manufacturing, distribution and research and development services that have been recorded as reductions to our cost of sales and research and development expenses. During 2001, we entered into a royalty agreement with Nihon Millipore, which provides Nihon Millipore the right to use certain intellectual property that was developed by Mykrolis in connection with the bioscience business. As a result of this agreement, $0.6 million in royalty income from Millipore was recognized and recorded in other income (expense), net for the years ended December 31, 2002 and 2001.

Millipore used a centralized approach to cash management and the financing of its operations. Prior to the Separation, our cash deposits were transferred to Millipore on a regular basis and netted against Millipore’s net investment. As a result, none of Millipore’s cash, cash equivalents or debt at the corporate level were allocated to us in our combined financial statements through the second quarter of 2001. Changes in Millipore’s net investment include our net earnings plus net cash transfers to or from Millipore. After the Separation but prior to the IPO, cash deposits were netted against amounts outstanding under our separation revolving credit agreement with Millipore. From the IPO to Distribution Date, amounts due to Millipore were netted against amounts due from Millipore and reported as accounts payable—Millipore in our consolidated and combined financial statements. After Distribution Date, these transactions were reported as third party accounts payable and third party accounts receivable.

For the years ended December 31, 2002, 2001 and 2000 we purchased products from Millipore for inclusion in our products sold to third parties totaling $2.7 million, $3.0 million and $4.0 million, respectively. For the years ended December 31, 2002 and 2001, products sold to Millipore by us totaled $2.0 million and $1.6 million, respectively. For the year ended December 31, 2000, products sold to Millipore were not material.

Critical Accounting Policies and Significant Judgements and Accounting Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated and combined financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our judgments and estimates, including those related to revenues, accounts receivable, inventories, long-lived assets and goodwill, deferred tax assets, income tax contingencies, warranty obligations, restructuring charges, accrued pension and other

post-retirement benefit obligations, and litigation contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the consolidated and combined financial statements. The Company has reviewed these policies with its Audit and Finance Committee.

Our net sales consist of revenue from sales of products net of trade discounts and allowances. We recognize revenue when evidence of an arrangement exists, contractual obligations have been satisfied, title and risk of loss have been transferred to the customer and collection of the resulting receivable is reasonably assured. In the event significant post-shipment obligations or uncertainties remain, revenue is recognized when such obligations are fulfilled by us or the uncertainties are resolved. We provide for estimated product returns under limited contractual obligations. Amounts billed to customers that relate to shipping costs are included in net sales and in cost of sales. Revenue from services is recognized when the services are provided. Our service revenue was less than 3.0% of total net sales for each of the three years ended December 2002, 2001 and 2000.

We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments based upon specific identification, by customer. If the financial condition of our customers was to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

We provide reserves for estimated excess and obsolete inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. We fully reserve for inventories deemed obsolete. We perform quarterly reviews of all inventory items to identify excess and obsolete inventories on-hand by comparing on-hand balances to recent historical usage as well as anticipated or forecasted demand, based upon input from sales, research and development and marketing functions. If estimates of demand diminish further or actual market conditions are less favorable than those projected, additional inventory write-downs may be required. We adjust the cost basis of inventory that has been written down to reflect its net realizable value.

We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying value of an asset or class of assets may not be fully recoverable and exceeds its fair value. For long-lived assets we intend to hold and use, if the carrying amount of the asset exceeds the sum of undiscounted cash flows expected to result from the use of the asset over its useful life, an impairment loss will be recorded. The amount of the impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. Assets held for sale are valued at fair value less costs to sell the asset.

For goodwill, we assess fair value by measuring discounted cash flows and comparable company analysis for the applicable underlying reporting unit and test for impairment as the difference between the resulting implied fair value of goodwill compared to its recorded carrying value. Goodwill impairment is tested annually or whenever events and changes in circumstances occur.

The estimates of useful lives and expected cash flows require us to make significant judgments regarding future periods that are subject to some factors outside our control. Changes in these estimates can result in significant revisions to the carrying value of these assets and may result in material charges to the results of operations.

Our valuation allowance against the deferred tax assets are based on our assessment of historical pre-tax income and projected pre-tax income for early future periods. In addition, there is no valuation allowance against the deferred tax assets in foreign subsidiaries based on our assessment of historical pre-tax income and projected pre-tax income for early future periods. In the event the foreign subsidiaries do not generate sufficient pre-tax income as planned during 2003, we will need to re-evaluate whether it is more likely than not that certain deferred tax assets in the foreign subsidiaries will be realized.

Tax contingencies are recorded to address potential exposures involving tax positions we have taken that could be challenged by taxing authorities. These potential exposures result from the varying application of statutes, rules, regulations and interpretations. Our estimate of the value of our tax contingencies contains

assumptions based on past experiences and judgments about potential actions by taxing jurisdictions. It is reasonably likely that the ultimate resolution of these matters may be greater or less than the amount that we have accrued.

At the time revenue is recognized, we provide for the estimated cost of product warranties as provided for under our contractual arrangements. Our warranty obligation is affected by product failure rates and service delivery costs incurred in correcting a product failure. Should such failure rates or costs differ from these estimates, accrued warranty costs would be adjusted in the period that such events or costs become known.

During 2002 and 2001, we recorded significant charges to operations in connection with our restructuring programs. The related reserves reflect estimates, including those pertaining to severance costs and facility exit costs. We reassess the reserve requirements to complete each restructuring program at the end of each reporting period. Actual experience may be different from these estimates.

We have significant pension and post retirement benefit costs and credits, which are developed from actuarial valuations. Inherent in these valuations are key assumptions, including discount rates and expected return on plan assets, which are usually updated on an annual basis at the beginning of each fiscal year. We are required to consider current market conditions, including changes in interest rates, in making theses assumptions. Changes in the related pension and post retirement benefit costs or credits may occur in the future due to changes in assumptions.

We are subject to proceedings, lawsuits and other claims, including proceedings under laws and government regulations related to securities, environmental, labor, product and other matters. We are required to assess the likelihood of any adverse judgments or outcomes to these matters, as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies is based on a careful analysis of each individual issue with the assistance of outside legal counsel. The required reserves may change in the future due to new developments in each matter or changes in approach such as a change in settlement strategy in dealing with these matters.

During the fourth quarter of 2002, we recorded restructuring and other charges of $5.2 million to further respond to the current semiconductor industry downturn. Of this amount, $1.7 million relates to non-cash asset writedowns due to asset impairments. Key elements of these restructuring and other charges included:

These restructuring initiatives are expected to yield annualized savings of approximately $3.8 million. The savings will result from reduced wages and facility-related costs and depreciation. The savings will be reflected in costs of sales, selling, general and administrative expenses and research and development expenses.

During the third quarter of 2001, we recorded restructuring and other charges of $4.9 million in response to the prolonged duration and severity of the current semiconductor industry downturn. The restructuring and other charges included approximately $2.5 million of employee severance costs, a $0.7 million write-off of equipment and leasehold improvements and $1.7 million of net exit costs on leased property. Key initiatives of the restructuring included:

During the first quarter of 2001, we recorded restructuring and other charges of $12.6 million in connection with our separation from Millipore to improve our manufacturing asset utilization and resize our overall cost structure. These restructuring and other charges included approximately $11.3 million of employee severance costs resulting in the elimination of 205 positions worldwide, approximately $1.0 million of equipment and leasehold improvement write-offs and approximately $0.3 million of lease cancellation costs. Key initiatives included:

These combined 2001 restructuring initiatives resulted in annualized savings of approximately $16 million through reduced payroll costs, and facility-related costs and depreciation. The savings are reflected in costs of sales, selling, general and administrative expenses and research and development expenses.

As of December 31, 2002, our total accrued restructuring costs amount to $5.8 million. Of this amount, the majority of the $2.0 million in severance costs for terminated employees will be paid in the first quarter of 2003. The facilities-related costs of $3.8 million will be substantially paid by the fourth quarter of 2005.

In addition, in connection with continuing efforts to separate from Millipore and the implementation of our worldwide manufacturing strategy, we expect to incur incremental, non-recurring operating costs and expenses. During 2003, these incremental, separation related, non-recurring costs and expenses could amount to approximately $1.0 million. In 2002 and 2001, these costs and expenses amounted to approximately $2.4 million and $5.7 million, respectively. These costs and expenses are associated with legal fees, initial marketing expenses related to establishing a new brand identity, retention bonuses, depreciation expense due to decreases in the estimated useful lives of fixed assets and leasehold improvements, designing and constructing our computer infrastructure and implementing treasury, real estate, pension and records retention management services.

During the fourth quarter of 2002, we decided to establish a data center at the Billerica headquarters to handle data processing services that have been performed by Millipore. We expect that data processing operations will be operational by the end of the second quarter of 2003 and that future costs will be consistent with the historical costs incurred for these services. In 2003, we expect to incur approximately $1.0 million of separation costs associated with transitioning our data processing activities from Millipore.

The principal market we serve is the global semiconductor industry, a highly cyclical business. As a result, we have experienced significant variations in net sales and results of operations in the periods presented and such variations are likely to continue. We generally have limited backlog. We believe the business environment will remain uncertain, and there are no clear signs of an imminent industry upturn.

Throughout 2002 and 2001, we have experienced and we are continuing to experience weak demand for our liquid and gas delivery systems, components and consumables from a number of our large customers. These customers have placed fewer orders as they attempt, we believe, to manage their demand and their inventories in response to weakness in their market. As a result, our revenues and our operating results decreased in 2002 and 2001 as compared to prior years. We can not predict the extent or duration of this cyclical downturn or its impact on us.

We have taken actions to reduce capital expenditures, operating costs and expenses in response to these adverse trends. During the fourth quarter of 2002, we implemented several actions to reduce our cost structure and to streamline our organization. Our worldwide workforce was reduced by 7% and we announced the closing of our small manufacturing operation in San Clemente, California. However, in the midst of this downturn, we continue to support our customers around the world and to fund key research and development programs for future growth.

Our results of operations for the years ended December 31, 2002, 2001 and 2000 in dollars and as a percentage of total net sales were as follows:

Year Ended December 31, 2002 Compared to Years Ended December 31, 2001 and 2000

Net Sales. Net sales were $178.4 million in 2002, which represented a 17.1%, or a $36.9 million decrease when compared to 2001. This decrease was a result of the severe downturn in the semiconductor industry, which began in the first quarter of 2001. The decline in sales was significant in most geographic regions and across nearly all product families. Sales of microelectronics equipment have declined as new semiconductor fabrication plant construction and upgrades have declined due to industry over-capacity. In addition, sales of consumable purification products also declined, although to a lesser extent, as semiconductor fabrication plants have experienced lower manufacturing volumes and have focused on achieving manufacturing efficiencies and reducing material costs.

During 2001, net sales decreased 39.4% or $140.2 million from $355.5 million in 2000. The net sales decrease in 2001 was primarily due to a rapid decline in the semiconductor industry that severely impacted our business. New semiconductor plant construction and upgrades began to decline rapidly in the first quarter of 2001 due to industry-wide over-capacity and resulted in a decline in our microelectronics equipment sales. In addition, sales of consumable products also declined, although to a lesser extent, as semiconductor fabrication plants focused on achieving manufacturing efficiencies and reducing materials costs.

Net sales and net sales change over the years ended December 31, 2002, 2001 and 2000, by geography, are summarized in the table below.

During 2002 as compared to 2001, the Japanese yen was essentially flat against the U.S. dollar, while the South Korean won, the Singapore dollar and the Euro strengthened by 5.5%, 2.8% and 10.2%, respectively. During 2001 as compared to 2000, the Japanese yen, the South Korean won, the Singapore dollar and the Euro weakened against the U.S. dollar by approximately 13.0%, 11.2%, 4.6% and 3.0%, respectively.

Gross Profit Margins. Gross profit margins were 33.4% in 2002, 36.1% in 2001 and 50.9% in 2000. The decrease in 2002 is primarily due to reductions in product demand and production volume resulting in lower overhead absorption. We responded to this lower demand by further consolidating our manufacturing operations. Gross profit margins in 2002 reflected $8.4 million of separation-related charges to operations. These charges included $1.7 million of redundant facility and labor expenses in order to ensure a smooth transfer from Millipore facilities into our new Billerica facility, $1.0 million of impairment charges associated with surplus manufacturing machinery which was ultimately sold, and net excess and obsolete inventory charges of $5.7 million. The gross profit margin decrease in 2001 over 2000, was primarily the result of lower manufacturing volumes. Gross profit margins in 2001 reflected $0.9 million of separation related, non-recurring charges.

Selling, General and Administrative Expenses. Selling, general and administrative expenses decreased 16.0% to $67.8 million in 2002 from $80.7 million in 2001. The decrease in 2002 from 2001 levels was attributable to results of the downsizing and restructuring programs initiated in 2001, as well as a series of actions to reduce discretionary spending in response to the current industry downturn. Selling, general and administrative expenses in 2001 decreased 16.3% in 2001 from $96.4 million in 2000 as a result of the 2001 restructuring initiatives.

Research and Development Expenses. Research and development expenses of $19.7 million in 2002 were essentially flat from 2001, which were $19.8 million. We intend to continue to fund key research and development programs despite the current business conditions. Research and development expenses decreased 14.7% in 2002 from $23.1 million in 2000. Key elements of our 2002 and 2001 research and development expenses were related to the continued development of the next generation 300mm products in the area of copper electrochemical plating, chemical mechanical planarization and deep ultra-violet photolithography applications. Additional investments were made to develop future generation of gas flow measurement and control products, chemical management technologies for advanced wafer clean applications, as well as DeviceNet^™ enabled product lines. During 2000, we focused on novel technology development and licensing for advanced copper interconnect and photolithography applications. Additional investments were made to develop in-house copper plating capability. We also focused on photochemical dispense systems, which are specifically designed to address advanced deep ultra-violet photolithography. We believe that our customers will migrate toward the 0.13 micron technology during the next upturn and that our new generation of high value added products resulting from these research and development investments are well positioned to respond to this trend.

Restructuring and Other Charges. Our operating results in 2002 included a total of $5.2 million of restructuring and other charges. During the fourth quarter of 2002, we recorded charges of $1.9 million related to the decision to close our San Clemente, CA manufacturing plant, severance costs of $1.6 million, and additional facilities exit costs of $1.7 million related to facilities that are closed in Bedford, MA and Swindon, England.

Our operating results in 2001 included a total of $17.5 million of restructuring and other charges. During the first quarter of 2001, we recorded restructuring and other charges of $12.6 million in connection with our separation from Millipore to improve our manufacturing asset utilization and resize our overall cost structure. The restructuring and other charges included $11.3 million of employee severance costs, a $1.0 million write-off of equipment and leasehold improvements and $0.3 million of lease cancellation costs. During the third quarter of 2001, we recorded an additional restructuring charge of $4.9 million in response to the prolonged duration and severity of the semiconductor industry downturn. This restructuring charge included $2.5 million of employee severance costs, a $0.7 million write-off of equipment and leasehold improvements, and $1.7 million of exit costs on leased property.

Other Income (Expense), Net. In 2002, other income (expense), net includes foreign currency transaction exchange gains of $1.6 million, interest income of $1.1 million, royalty income from Millipore of $0.6 million and $0.1 million other income. In 2001, other income (expense), net includes foreign currency transaction exchange losses of $2.2 million and a $0.4 million loss on investments in 20%-50% owned entities accounted for under the equity method offset by interest income of $0.7 million, royalty income from Millipore of $0.6 million and $0.2 million other income. In 2000, other income (expense), net included the $3.0 million write-off of investment holdings in a privately held U.S. company offset by $0.9 million in foreign currency transaction exchange gains and income of $0.7 million on investments in 20%-50% owned entities accounted for under the equity method.

Income Tax Expense. Prior to the Distribution Date, our operating results were included in Millipore’s consolidated U.S. and state income tax returns and in tax returns of certain Millipore foreign subsidiaries. Accordingly, income taxes were calculated on a separate return basis as if we filed tax returns separately from Millipore. At December 31, 2001, we had a $9.0 million income tax receivable related to net operating loss carrybacks determined on a separate return basis. In accordance with the tax sharing agreement, during 2002, Millipore decided not to allow us to carryback these net operating losses. As a result, the receivable was transferred to Millipore during 2002 and is reflected in the consolidated financial statements as a reduction to additional paid-in capital included in shareholders’ equity. Millipore managed its consolidated tax position for the benefit of its entire portfolio of businesses, and its tax strategies were not necessarily reflective of the tax strategies that we would have followed as a stand-alone company.

In 2002, we recorded income tax expense of $2.1 million on a pre-tax loss of $29.6 million. The income tax expense includes settlements from foreign tax audits for which we are responsible under our tax sharing agreement with Millipore and other income tax expense in our foreign operations.

In 2001, we recorded income tax expense of $26.2 million on a pre-tax loss of $41.4 million. This expense is primarily attributable to the valuation allowance against foreign tax credits on unremitted earnings of our foreign subsidiaries of approximately $18.0 million and other U.S. deferred tax assets of approximately $11.2 million. Statement of Financial Accounting Standards (“SFAS”) 109, “Accounting for Income Tax,” requires that we establish a valuation allowance or reserve when, based on an evaluation of objective verifiable evidence, we believe there is a likelihood that some portion or all of the deferred tax assets will not be realized. In 2001, we recorded a valuation allowance for the majority of these tax assets based on our assessment of historical pre-tax income and the significant deterioration in our projected pre-tax income for early future periods given the significant uncertainty surrounding the prolonged cyclical downturn in the semiconductor industry.

Our valuation allowance against the deferred tax assets is based on our assessment of historical pre-tax income and projected pre-tax income for early future periods. We are undertaking tax planning initiatives designed to generate future U.S. taxable income. As we generate future taxable income in the U.S. against which these tax assets may be applied, some portion or all of the valuation allowance would be reversed and an increase in net income would consequently be reported in future years. In addition, we continuously evaluate our tax position and our effective tax rate depending on changes in the geographic mix of our earnings and the continued development of our tax strategies.

In 2000 we recorded income tax expenses of $22.9 million on pre-tax income of $60.3 million.

Our principal cash requirements have been to fund our operations and additions to property, plant and equipment in connection with our new Billerica facility and our separation from Millipore. Until our separation from Millipore, effective March 31, 2001, Millipore managed our overall capital requirements on a centralized basis including management of cash and debt. Millipore retained cash receipts associated with our business on a daily basis and provided funds to cover our disbursements. Accordingly, we have reported neither cash or cash equivalents nor debt at December 31, 2000.

Cash provided by operating activities was $7.5 million during the year ended December 31, 2002, as compared to $18.1 million during the year ended December 31, 2001. During 2002, cash provided by operating activities resulted primarily from our decrease in inventory of $21.0 million. This increase to cash was offset by our net loss of $31.8 million, after adjusting for the non-cash charges of $10.9 million for depreciation and amortization, $5.2 million related to restructuring and other charges and $1.0 million arising from impaired assets. In 2001, cash provided by operating activities resulted from a series of initiatives aimed at optimizing our working capital. In the second half of 2001, our gross inventory was reduced by $9.9 million. On a full year basis our gross inventory increased by $3.7 million. The collection of accounts receivable contributed $54.4 million offset by the reduction in accounts payable of $16.5 million and the change in other operating assets and liabilities of $12.8 million. Our cash flows from operations reflected a net use of cash of $10.0 million in 2000. The cash flows used in operations in 2000 was primarily attributed to growth in accounts receivable and inventory due to a significant sales volume increase that more than offset increased net income. Inventory levels increased due to stocking levels of new products and efforts to increase customer service levels through increased product availability.

Cash flow used in investing activities consisted of capital expenditures for property, plant and equipment of $17.9 million, $10.5 million and $11.8 million in the years ended December 31, 2002, 2001 and 2000, respectively. In 2002 and 2001, cash flows used in investing activities were primarily for the construction and purchase of production and research and development equipment, and the transfer of manufacturing operations from Millipore facilities pursuant to our separation agreement. Expenditures in 2000 were primarily on machinery and equipment in our manufacturing facilities to increase capacity to support increased demand for our products. During 2003, we expect to spend between $7.0 million to $10.0 million on capital expenditures primarily related to the purchase of manufacturing and research and development equipment.

Cash flows provided by financing activities for the year ended December 31, 2002 were $1.7 million and resulted from net transfers of $1.4 million from Millipore in accordance with our transition service agreements and Separation from Millipore and $1.9 million generated by the issuance of 223,648 shares of common stock under our employee stock purchase and stock option plans. This was offset by $1.6 million in cash collateralization related to a security deposit under a new lease for our corporate headquarters, research and development and manufacturing facility and other security deposits. At December 31, 2002, this cash collateral was invested in U.S. federal agency securities and money market funds. Cash flows from financing activities of $75.6 million for the year ended December 31, 2001 resulted from the receipt of $94.0 million of net proceeds from the sale of our stock in our initial public offering and net transfers from Millipore of $0.7 million offset by the payment of a $19.1 million Separation Note to Millipore. From April 1, 2001 through the consummation of our initial public offering in August 2001, Millipore provided a line of credit to us pursuant to a separation revolving credit agreement to support our cash requirements. We borrowed $27.5 million under this separation revolving credit agreement with Millipore that was repaid from the proceeds of our initial public offering. The amount of the Separation Note represented amounts determined by agreement between us and Millipore to ensure that all net proceeds of our initial public offering in excess of $75.0 million would be payable to Millipore. Cash flows from financing activities for the year ended December 31, 2000 were $21.9 million and resulted from capital contributions from Millipore. These cash transfers from Millipore for the year ended December 31, 2000 reflect changes in the cash financing required to fund our capital expenditures and operating activities.

Our liquidity is affected by many factors, some of which are based on the normal ongoing operations of our business and some of which arise from uncertainties related to global economies. We believe that our cash and cash equivalents together with expected cash collections from existing trade receivables will be sufficient to satisfy our working capital, capital expenditure, restructuring and research and development requirements and other committments for the next twelve months. We expect that our cash flow needs beyond this twelve-month period will be satisfied through cash flow generated from operations.

If our cash flows from operations are less than we expect beyond this twelve month period, we may need to incur debt or issue additional equity. Also, we may need to incur debt or issue equity to make strategic acquisitions or investments. There can be no assurance that we will be able to obtain necessary financing on favorable terms or at all. If we are unable to obtain necessary financing beyond this twelve month period, we may not have sufficient cash to operate our business.

Under accounting principles generally accepted in the U.S., certain obligations and commitments are not required to be included in the consolidated balance sheet and statement of operations. These obligations and commitments, while entered into in the normal course of business, may have a material impact on liquidity. The following commitments as of December 31, 2002 have not been included in the consolidated balance sheet and statement of operations included under Item 8. Financial Statements and Supplemental Data, however, they have been disclosed in the following table in order to provide a more accurate picture of our financial position and liquidity. We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

Pursuant to the terms of the lease for our vacated Bedford, Massachusetts facility, the landlord has an option to sell the facility to us at any time prior to November 2005, the end of the lease term, at 90% of the then current market value, excluding the value of the lease.

Historically, our exposure to foreign currency exchange rate risk had been managed on an enterprise-wide basis as part of Millipore’s risk management strategy. We do not currently hold derivative financial instruments and continue to evaluate our future hedging strategy. We sell our products in many countries and a substantial portion of our net sales and a portion of our costs and expenses are denominated in foreign currencies. Approximately 69% of our net sales in the year ended December 31, 2002 were derived from customers located outside of the U.S., principally in Asia including Japan, where we also manufacture some of our products. This exposes us to risks associated with changes in foreign currencies that can adversely impact revenues, net income and cash flow. In addition, we are potentially subject to concentrations of credit risk, principally in accounts receivable, as historically we have relied on a limited number of customers for a substantial portion of our net sales. We perform ongoing credit evaluations of our customers and we generally do not require collateral. Our major customers are large, well-established microelectronics companies that have historically paid their accounts receivable balances with us.

We adopted Financial Accounting Standards Board (the “FASB”) SFAS No. 142 on January 1, 2002. We performed an assessment of whether there was an indication that goodwill was impaired at the date of adoption. We determined that, for purposes of this assessment, our business consists of liquid products and gas products reporting units and that our goodwill is attributable solely to the gas products reporting unit. We estimated the gas products reporting unit’s fair value, as determined by an independent valuation services company, and compared it to the carrying value of the net assets of this reporting unit. As of January 1, 2002 and December 31, 2002, the gas reporting unit’s fair value exceeded its value of the net assets, and therefore goodwill was not impaired. Goodwill amortization expense was $0.9 million and $1.0 million for the years ended December 31, 2001 and 2000, respectively. As a result of our adoption of SFAS 142, we ceased our goodwill amortization effective January 1, 2002. We estimate that goodwill amortization expense would have been approximately $0.9 million for the year ended December 31, 2002.

In August 2001, the FASB issued SFAS No. 143, “Accounting for Asset Retirement Obligations”, which provides the accounting requirements for retirement obligations associated with tangible long-lived assets. This Statement requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred. This Statement is effective for the Company’s 2003 fiscal year, and early adoption is permitted. The adoption of SFAS 143 is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows.

In October 2001, the FASB issued SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”. The objectives of SFAS 144 are to address significant issues relating to the implementation of FASB Statement 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of” and to develop a single accounting model, based on the framework established in SFAS 121, for long-lived assets to be disposed of by sale, whether previously held and used or newly acquired. SFAS 144 is effective for financial statements issued for fiscal years beginning after December 15, 2001, and generally its provisions are to be applied prospectively. We adopted this standard effective January 1, 2002.

In June 2002, the FASB issued SFAS No. 146, “Accounting for Exit or Disposal Activities”. SFAS 146 addresses significant issues regarding the recognition, measurement and reporting of costs that are associated with exit and disposal activities, including restructuring activities that are currently accounted for under Emerging Issues Task Force No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit and Activity (including Certain Costs Incurred in a Restructuring)” (“EITF 94-3”). The scope of SFAS 146 also includes costs related to terminating a contract that is not a capital lease and termination benefits that employees who are involuntarily terminated receive under the terms of a one-time benefit arrangement that is not an ongoing benefit arrangement or an individual deferred compensation contract. We are required to adopt the provisions of SFAS 146 effective for exit or disposal activities initiated after December 31, 2002. The provisions of EITF 94-3 shall continue to apply for any exit activity initiated under an exit plan that met the criteria of EITF 94-3 prior to adoption of SFAS 146. The adoption of SFAS 146 will change, on a prospective basis, the timing of recording restructuring charges from the commitment date to when the liability is incurred. We will adopt this standard for restructuring activities initiated subsequent to December 31, 2002.

In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure—an Amendment of FASB Statement No. 123”, which is effective for financial statements for fiscal years ending after December 15, 2002, with early adoption permitted. SFAS 148 will enable companies that choose to adopt the preferable fair value method to report the full effect of employee stock options in their financial statements immediately upon adoption, and to make available to investors better and more frequent disclosure about the cost of employee stock options. We will continue to apply the disclosure only provisions of both SFAS 123 and SFAS 148.

In November 2002, the FASB issued FASB Interpretation (“FIN”) No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” FIN No. 45 clarifies that a guarantor is required to recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The initial recognition and initial measurement provisions of FIN No. 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002. The disclosure requirements of FIN No. 45 are applicable for financial statements of interim periods ending after December 15, 2002 and are included in Note 16 to the condensed consolidated and combined financial statements.

In November 2002, the EITF issued No. 00-21, “Accounting for Revenue Arrangements with Multiple Deliverables.” EITF No. 00-21 addresses certain aspects of the accounting by a vendor for arrangements under which it will perform multiple revenue-generating activities. EITF No. 00-21 establishes three principles: revenue should be recognized separately for separate units of accounting, revenue for a separate unit of accounting should be recognized only when the arrangement consideration is reliably measurable and the earnings process is substantially complete, and consideration should be allocated among the separate units of accounting in an arrangement based on their fair values. EITF No. 00-21 is effective for all revenue arrangements entered into in fiscal periods beginning after June 15, 2003, with early adoption permitted. We are evaluating the impact, if any, that this pronouncement will have on our consolidated financial statements.

In January 2003, the FASB issued FIN No. 46 “Consolidation of Variable Interest Entities, an interpretation of ARB 51.” FIN 46 provides guidance on the identification of entities for which control is achieved through means other than through voting rights called “variable interest entities” or “VIEs” and how to determine when and which business enterprise should consolidate the VIE (the “primary beneficiary”). This new model for consolidation applies to an entity which either (1) the equity investors (if any) do not have a controlling financial interest or (2) the equity investment at risk is insufficient to finance that entity’s activities without receiving additional subordinated financial support from other parties. In addition, FIN 46 requires that both the primary beneficiary and all other enterprises with a significant variable interest in a VIE make additional disclosures. Certain transitional disclosures are required in financial statements initially issued after January 31, 2003, if it is reasonably possible that once this guidance is effective the enterprise will either be required to consolidate a variable interest entity or will hold a significant variable interest in a variable interest entity. We do not believe that we have any interests that would change our current reporting entity or require additional disclosures outlined in FIN 46.

The matters discussed in this Annual Report on Form 10-K, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current management expectations and are subject to substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. When used herein or in such statements, the words “anticipate”, “believe”, “estimate”, “expect”, “may”, “will”, “should” or the negative thereof and similar expressions as they relate to Mykrolis or its management are intended to identify such forward-looking statements. Potential risks and uncertainties that could affect our future operating results include the risk factors described elsewhere in this Annual Report on Form 10-K as well as the following:

Our business depends substantially on semiconductor industry capital spending, which is characterized by periodic fluctuations that may cause a reduction in demand for our products.

Our business depends substantially upon the capital expenditures of semiconductor device manufacturers, which in turn depend upon the demand for semiconductors and other products utilizing semiconductors. We estimate that approximately 90% of our sales during 2002, 2001 and 2000 were to semiconductor capital equipment manufacturers and semiconductor device manufacturers, and we expect that sales to such customers will continue to account for a substantial majority of our sales. Reductions in demand for the products manufactured by semiconductor capital equipment manufacturers and semiconductor device manufacturers will restrict our ability to grow our business and cause our sales and profitability to decline. Historically, the semiconductor market has been highly cyclical and has experienced periods of overcapacity, resulting in significantly reduced demand for capital equipment used to make semiconductors. For example, during fiscal 2002 and 2001 the semiconductor industry has experienced a significant decline, which has caused a number of our customers to reduce their orders. Our net sales for 2002 were approximately $178.4 million, representing a decline of $36.9 million, or 17.1% from our net sales in 2001. Our net sales for 2001 were $215.3 million, representing a $140.2 million, or 39.4%, decline from our net sales in 2000. We also experienced downturns in 1996 and 1998. During the 1998 downturn, our annual net sales declined approximately $82.9 million, or 31% from the prior year. There is typically a three to six month lag between a change in capital expenditures within the semiconductor industry and the related impact on the demand for our products. If the current downturn continues for any significant period of time, it will further inhibit our growth and cause our sales and profitability to decline significantly.

The semiconductor industry is subject to rapid demand shifts which are difficult to predict. As a result, our inability to meet demand in response to these rapid shifts may cause a reduction in our market share.

Our ability to increase sales of our products, particularly our capital equipment products, depends in part upon our ability to ramp up the use of our manufacturing capacity for such products in a timely manner and to mobilize our supply chain. In order to meet the demands of our customers, we may be required to ramp up our manufacturing capacity in as little as a few months. If we are unable to expand our manufacturing capacity on a timely basis or to manage such expansion effectively, our customers could seek such products from other suppliers, and our market share could be reduced. Because demand shifts in the semiconductor industry are rapid and difficult to foresee, we may not be able to increase capacity quickly enough to respond to such an increase in demand.

Our annual and quarterly operating results are subject to fluctuations as a result of rapid demand shifts and our insignificant level of backlog and if we fail to meet the expectations of securities analysts or investors, our share price may decrease significantly.

Our sales and operating results can vary significantly from quarter to quarter and year to year. Because our expense levels are relatively fixed in the short-term, an unanticipated decline in revenue in a particular quarter could disproportionately affect our net income in that quarter. In addition, we make a substantial portion of our shipments shortly after we receive the order, and therefore we operate with an insignificant level of backlog. As a consequence of the just-in-time nature of shipments and the low level of backlog, our results of operations may decline quickly and significantly in response to changes in order patterns or rapid decreases in demand for our products. We anticipate that fluctuations in operating results will continue in the future. Such fluctuations in our results could cause us to fail to meet the expectations of securities analysts or investors, which could cause our share price to decline substantially. We believe that period-to-period comparisons of our results of operations may not be meaningful, and you should not rely upon them as indicators of our future performance.

When the semiconductor industry rebounds it may not rebound to historic levels but may rather reflect a lower rate of growth consistent with the electronics industry.

Notwithstanding two years of severe and prolonged downturn, many commentators observe that the semiconductor industry still has excess manufacturing capacity. In addition there currently does not appear to be a major application that would drive growth coming out of the downturn, as was the case in 1998 with telecommunications and internet applications Accordingly some analysts have predicted that the semiconductor industry may experience lower growth during its recovery cycles and that its longer term performance may become similar to that of the electronics industry.

If we are unable to maintain our technological expertise in design and manufacturing processes, we will not be able to successfully compete.

We believe that our future success will depend upon our ability to develop and provide products that meet the changing needs of our customers, including the transition from the use of 200 millimeter wafers to 300 millimeter wafers, the shrinking of integrated circuit line-widths and the use of new classes of materials, such as copper, titanium nitride and organic and inorganic dielectric materials, which are materials that have either a low or high resistance to the flow of electricity. This requires that we successfully anticipate and respond to technological changes in manufacturing processes in a cost-effective and timely manner. Our inability to develop the technical specifications for any of our new products or enhancements to our existing products or to manufacture and ship these products or enhancements in volume in a timely manner could harm our business prospects and significantly reduce our sales. In addition, if new products have reliability or quality problems, we may experience reduced orders, higher manufacturing costs, delays in acceptance and payment, additional service and warranty expense and damage to our reputation.

Our competitive position will be weakened if semiconductor device manufacturers do not require semiconductor capital equipment manufacturers to design our products into new generations of their equipment.

New products designed by semiconductor capital equipment manufacturers typically have a lifespan of five to ten years. Our competitive success depends on our products being designed into new generations of equipment for the semiconductor industry. In some cases, semiconductor device manufacturers may direct semiconductor capital equipment manufacturers to use a specified supplier’s product in their equipment. Accordingly, our success will depend in part on our ability to have semiconductor device manufacturers specify that our products be used at their semiconductor fabrication facilities. If our products are not specified by semiconductor equipment manufacturers, our net sales may be reduced during the lifespan of our customers’ products.

Because our sales are concentrated on a small number of key customers, our revenue and profitability may materially decline if one or more of our key customers do not continue to purchase our existing and new products in significant quantities.

We depend and expect to continue to depend on a small number of customers for a large portion of our business, and changes in our customers’ orders have had a significant impact on our operating results. In 2002, 2001 and 2000, our top customer accounted for approximately 13%, 14% and 18%, respectively, of our net sales. In those same periods, net sales to our ten largest customers accounted for approximately 35%, 33% and 39%, respectively, of our net sales. In addition, we sell products to systems integrators who then sell components, which include our products, to some of our major customers. If any one of our key customers decides to purchase significantly less from us or to terminate its relationship with us, our revenue and profitability may decline significantly. We could lose our key customers or significant sales to our key customers because of factors beyond our control, such as a significant disruption in our customers’ businesses generally or in a specific product line. For example, we are currently experiencing softening demand for our products as a result of the downturn in the semiconductor industry. These customers may stop incorporating our products into their

products with limited notice to us and suffer little or no penalty for doing so. In addition, if any of our customers merge, we may experience lower overall sales from the merged companies. Because one of our strategies has been to develop long-term relationships with a few key customers in the product areas in which we focus and because we have a long product design and development cycle for most of our products and prospective customers typically require lengthy product qualification periods prior to placing volume orders, we may be unable to replace these customers quickly or at all.

Because we are subject to order and shipment uncertainties and many of our costs are fixed, any significant changes, cancellations or deferrals could cause our revenue and profitability to decline or fluctuate.

As is typical in the microelectronics industry, we do not usually obtain long-term purchase orders or commitments from our customers. Instead, we work closely with our customers to develop non-binding forecasts of the future volume of orders. Customers may cancel their orders, change production quantities from forecasted volumes or delay production for reasons beyond our control. Order cancellations or deferrals could cause us to hold inventory for longer than anticipated, which could reduce our profitability, restrict our ability to fund our operations and cause us to incur unanticipated reductions or delays in our revenue. Our customers often change their orders multiple times between initial order and delivery. Such changes usually relate to quantities or delivery dates, but sometimes relate to the specifications of the products we are supplying. If a customer does not timely pay for these products, we could incur significant charges against our income. In addition, our profitability may be affected by the generally fixed nature of our costs. Because a substantial portion of our costs are fixed, we may experience and currently are experiencing deterioration in gross margins when volumes decline. From time to time, we make capital investments in anticipation of future business opportunities. If we are unable to obtain the anticipated business, our revenue and profitability may decline.

Competition from existing or new companies in the microelectronics industry could cause us to experience downward pressure on prices, fewer customer orders, reduced margins, the inability to take advantage of new business opportunities and the loss of market share.

We operate in a highly competitive industry. We compete against many domestic and foreign companies that have substantially greater manufacturing, financial, research and development and marketing resources than we do. In addition, some of our competitors may have more developed relationships with our existing customers than we do, which may enable them to have their products specified for use more frequently by these customers. We also face competition from the manufacturing operations of our current and potential customers, who continually evaluate the benefits of internal manufacturing versus outsourcing. As more original equipment manufacturers dispose of their manufacturing operations and increase the outsourcing of their products to liquid and gas delivery system and other component companies, we may face increasing competitive pressures to grow our business in order to maintain our market share. If we are unable to maintain our competitive position, we could experience downward pressure on prices, fewer customer orders, reduced margins, the inability to take advantage of new business opportunities and a loss of market share.

We conduct a significant amount of our sales activity and manufacturing efforts outside the United States, which subjects us to additional business risks and may cause our profitability to decline due to increased costs.

Sales by our international subsidiaries to customers outside the United States accounted for approximately 69% of our net sales in 2002, 67% of our net sales in 2001, 61% of our net sales in 2000. We anticipate that international sales will continue to account for a majority of our net sales. In addition, a number of our key domestic customers derive a significant portion of their revenues from sales in international markets. We also manufacture a significant portion of our products outside the United States and are dependent on international suppliers for many of our parts. We intend to continue to pursue opportunities in both sales and manufacturing

internationally. Our international operations are subject to a number of risks and potential costs that could adversely affect our revenue and profitability, including:

In the past, we have incurred costs or experienced disruptions due to the factors described above and expect to do so in the future. For example, our operations in Asia, and particularly Korea, Taiwan and Japan, have been negatively impacted in the past as a result of regional economic instability, most recently in 1998. In addition, Taiwan and Korea account for a growing portion of the world’s semiconductor manufacturing. There are currently strained relations between China and Taiwan and there are growing tensions between North Korea and South Korea and the United States. Any adverse developments in those relations could significantly disrupt the worldwide production of semiconductors, which would lead to reduced sales of our products.

Fluctuations in the value of the U.S. dollar in relation to other currencies may lead to lower net income or may cause us to raise prices, which could result in reduced sales.

Foreign currency exchange rate fluctuations could have an adverse effect on our net sales and results of operations. Approximately 69% of our net sales in 2002, 67% of our net sales in 2001 and 61% of our net sales in 2000 were denominated in foreign currencies. Unfavorable foreign currency fluctuations could require us to increase prices to foreign customers, which could result in lower net sales by us to such customers. Alternatively, if we do not adjust the prices for our products in response to unfavorable foreign currency fluctuations, our profitability could decline. In addition, sales made by our foreign subsidiaries are denominated in the currency of the country in which these products are sold, and the currency we receive in payment for such sales could be less valuable at the time of receipt versus the time of sale as a result of foreign currency exchange rate fluctuations.

We incur significant cash outlays over lengthy time periods in order to research, develop, manufacture and market new products, which may never reach market or may have limited market acceptance.

We make significant cash expenditures to research, develop and market new products. For example, we incurred $19.7 million of research and development expense in 2002, $19.8 million in 2001 and $23.2 million in 2000. The development period for a product can be as long as five years. Following development, it may take an additional two to three years for the market size of that product to reach a substantial level. We cannot be certain of the success of a new product. A product concept may never progress beyond the development stage or may only achieve limited acceptance in the marketplace. If this occurs, we do not receive a direct return on our expenditures and may not even realize any indirect benefits. Additionally, capacity expansion may be necessary in order to manufacture a new product. If sales levels do not increase to offset the additional fixed operating expenses associated with any such expansion, our revenue and profitability could decline and our prospects could be harmed.

We depend on our suppliers for our raw materials and components, and our production would be substantially curtailed if these suppliers are not able to meet our demands and alternative sources are not available.

We purchase raw materials and components from third parties to complete our customers’ orders, and some of these raw materials and components may, in the future, need to be ordered from sole-source suppliers.

Although we work with our customers and suppliers to minimize the impact of shortages in raw materials and components, we sometimes experience short-term adverse effects due to price fluctuations and delayed shipments. In the past, there have been industry-wide shortages of electronic components, particularly memory and logic devices. If a significant shortage of raw materials or components were to occur, we may have to delay shipment. Supply shortages of particular components will likely substantially curtail production of products using these components. In addition, while many of our significant customer contracts permit periodic reviews of pricing based on decreases and increases in the prices of raw materials and components, we are not always able to pass on price increases to our customers and significant price increases from our suppliers could cause our profitability to decline. The loss of any of these or other significant suppliers, delays in shipments, the inability of a supplier to meet performance and quality specifications or delivery schedules or our inability to pass along price increases could cause our revenue and profitability to decline significantly.

We may acquire other businesses or form joint ventures that could negatively affect our profitability, increase our debt and dilute your ownership of our company.

As part of our business strategy, we expect to address gaps in our product offerings, diversify into complementary product markets or pursue additional technology and customers through acquisitions or joint ventures. As a result, we may enter markets in which we have no or limited prior experience. Competition for acquiring attractive businesses in our industry is substantial. In executing this part of our business strategy, we may experience difficulty in identifying suitable acquisition candidates or in completing selected transactions at appropriate valuations. If we were to make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business and we could assume unknown or contingent liabilities or experience negative effects on our reported results of operations from dilutive results from operations and/ or from future potential impairment of acquired assets. We may experience difficulties in operating in foreign countries or over significant geographical distances and in retaining key employees or customers of an acquired business, and our management’s attention could be diverted from other business issues. We may not identify or complete these transactions in a timely manner, on a cost effective basis or at all, and we may not realize the benefits of any acquisition or joint venture.

We may not be able to obtain financing to fund our future capital requirements, including strategic acquisitions, on favorable terms or at all; the amount of equity we can issue may likewise be limited. This could prevent us from addressing gaps in our product offerings, improving our technology or increasing our manufacturing capacity.

If our cash flows from operations are less than we expect, we may need to issue additional equity or incur debt. There can be no assurance that we will be able to obtain necessary short-term or other financing on favorable terms or at all. If we are unable to obtain necessary financing, we may not have sufficient cash to operate our business. In particular, we expect to fund future acquisitions in whole or in part by issuing additional equity. Any equity issued would dilute your ownership of us. If the price of our equity is low or volatile, we may not be able to issue equity to acquire other companies and our acquisition strategy could require us to incur substantial amounts of indebtedness. We will likely not be able to obtain financing with interest rates as favorable as those that we could obtain as a part of Millipore. While we currently have no debt outstanding, potential future levels of indebtedness could have consequences for our business, including:

Furthermore, if we raise funds through the issuance of debt, the debt securities issued will likely have rights, preferences and privileges senior to those of holders of our common stock in the event of a liquidation or otherwise, and the terms of the debt securities may impose restrictions on our operations. We cannot assure you that financing for acquisitions will be available on terms acceptable to us, or at all.

Loss of any of our key personnel could hurt our business because of their experience in the microelectronics industry and their technological expertise. Similarly, our inability to attract and retain new qualified personnel could inhibit our ability to operate and grow our business successfully.

We depend on the services of our key senior executives and other technological experts because of their experience in the microelectronics industry and their technical expertise. The loss of the services of one or several of our key employees or an inability to attract, train and retain qualified and skilled employees, specifically R & D and engineering personnel, could result in the loss of customers or otherwise inhibit our ability to operate and grow our business successfully. In particular, since our separation from Millipore, we have had to develop and implement a new administrative and managerial infrastructure. Our future success depends on the successful development and implementation of this infrastructure and our ability to expand, integrate and retain our management team. We have also had to impose salary reductions on our senior employees and freeze merit increases in order to maintain our financial position during the current extended downturn in the semiconductor industry; this may make it more difficult to attract and retain key personnel. In addition, our ability to successfully integrate acquired facilities or businesses depends, in part, on our ability to retain and motivate key management and employees hired by us in connection with the acquisition.

If we are unable to protect our intellectual property rights, our business and prospects could be harmed.

Our future success and competitive position depend in part upon our ability to obtain and maintain proprietary technology used in our principal product families. We rely, in part, on patent, trade secret and trademark law to protect that technology. We routinely enter into confidentiality agreements with our employees. However, there can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach or that our confidential and proprietary information and technology will not be independently developed by or become otherwise known to third parties. We have obtained a number of patents relating to our products and have filed applications for additional patents. We cannot assure you that any of our pending patent applications will be approved, that we will develop additional proprietary technology that is patentable, that any patents owned by or issued to us will provide us with competitive advantages or that these patents will not be challenged by third parties. Patent filings by third parties, whether made before or after the date of our filings, could render our intellectual property less valuable. Competitors may misappropriate our intellectual property, and disputes as to ownership of intellectual property may arise. In addition, if we do not obtain sufficient international protection for our intellectual property, our competitiveness in international markets could be significantly impaired, which would limit our growth and future revenue. Furthermore, there can be no assurance that third parties will not design around our patents.

Protection of our intellectual property rights may result in costly litigation.

We may from time to time be required to institute litigation in order to enforce our patents, copyrights or other intellectual property rights, to protect our trade secrets, to determine the validity and scope of the proprietary rights of others or to defend against claims of infringement. Such litigation could result in substantial costs and diversion of resources and could negatively affect our sales, profitability and prospects regardless of whether we are able to successfully enforce our rights. For example, in 1998, we settled a patent lawsuit in which each party claimed infringement of a patent by the other. In connection with the settlement, we incurred a charge of approximately $3.7 million and agreed to a cross-license of the two patents at issue. In connection with future intellectual property infringement claims, we will not have the benefit of asserting counterclaims based on Millipore’s intellectual property portfolio, and we will not be able to offer licenses to Millipore’s intellectual property in order to resolve claims.

Our ability to manufacture and sell our products and develop new products in response to competitive pressures could be restricted or delayed, and we could incur significant expenses, if we are unable to obtain necessary licenses to the proprietary technology of others.

We license and will continue to license technology used in the manufacture and distribution of our products from third parties. Our inability to acquire any third-party licenses, or integrate the related third-party technologies into our products, could result in delays in our product developments and enhancements until equivalent technologies can be identified, licensed or integrated. We may also require new licenses in the future as our business grows and technology evolves. We cannot assure you that these licenses will be available to us on commercially reasonable terms, if at all.

If we infringe on the proprietary technology of others, our business and prospects could be harmed.

Our commercial success will depend, in part, on our ability to avoid infringing or misappropriating any patents or other proprietary rights owned by third parties. If we are found to infringe or misappropriate a third party’s patent or other proprietary rights, we could be required to pay damages to such third party, alter our products or processes, obtain a license from the third party or cease activities utilizing such proprietary rights, including making or selling products utilizing such proprietary rights. If we are required to obtain a license from a third party, there can be no assurance that we will be able to do so on commercially favorable terms, if at all.

We are subject to a variety of environmental laws which could cause us to incur significant expenses.

In addition to other regulatory requirements affecting our business, we are subject to a variety of federal, state, local and foreign regulatory requirements relating to the use, disposal, clean-up of, and human exposure to, hazardous chemicals. We generate and handle materials that are considered hazardous waste under applicable law. If we fail to comply with any present or future regulations, we could be subject to future liabilities or the suspension of production. In addition, compliance with these or future laws could restrict our ability to expand our facilities or build new facilities or require us to acquire costly equipment, incur other significant expenses or modify our manufacturing processes.

We are currently consolidating manufacturing operations from our Yonezawa, Japan facility into our Billerica, MA headquarters, R&D and manufacturing facility. If we are unable to successfully manage this consolidation, our ability to deliver product to our customers could be disrupted and we could lose business.

In order to enhance the efficiency and cost effectiveness of our manufacturing operations we are moving several product lines from our Yonezawa, Japan plant to our Billerica facility. These product lines involve technically complex manufacturing processes that require considerable expertise to operate. If we are unable to complete this transfer in a systematic manner within established schedules or if we are unable to successfully operate these manufacturing processes in Billerica, production may be disrupted and we may not be able to deliver these products to meet customer orders in a timely manner and may lose business as a result.

Our pre-separation historical financial information may not be representative of our results as a stand-alone company and, therefore, may not be reliable as an indicator of our historical or future results.

We have only a limited operating history as an independent company. Prior to our separation from Millipore, Millipore did not account for us, and we were not operated, as a stand-alone entity. The historical combined financial information we have included in this report has been derived in part from Millipore’s consolidated financial statements and may not be indicative of our financial position, results of operations or cash flows in the future nor is it necessarily indicative of what our financial position, results of operations or cash

flows would have been had we been a stand-alone entity for all of the periods presented. This is primarily a result of the following factors:

Following our separation from Millipore, we have incurred incremental non-recurring operating costs and expenses associated with increased marketing expenses related to establishing a new brand identity, legal fees, retention bonuses, increased depreciation due to decreases in the estimated useful lives of fixed assets and leasehold improvements and other separation related costs. During 2003, we expect to incur approximately $1.0 million of such expenses associated with our separation from Millipore.

We have a limited history operating as a stand-alone company, and we may be unable to continue to effectively implement the changes necessary to operate as a stand-alone company, or we may incur greater costs as a stand-alone company that may cause our profitability to decline.

Prior to our separation, Millipore conducted our business as a division through various subsidiaries rather than as a stand-alone company. Accordingly, Millipore performed a number of corporate functions for us. In addition, until the spin-out distribution by Millipore, and in some cases even after the distribution, we have relied on Millipore for various transitional services. While, to date we have been successful at replacing these services at reasonable cost, there can be no assurance that we will continue to be able to do so. We currently continue to use Millipore’s information technology (“IT”) operations group to support and operate our data processing systems. Our IT systems have been modified from the Millipore systems, and are in the process of being further modified, to implement a new version of the enterprise resource planning system used by Millipore, which will enable us to better support our business. These modifications, however, may result in unexpected system failures or the loss or corruption of data. We are also in the process of creating our own IT infrastructure to replace many of the IT services that Millipore provides us. We may not be successful in executing this transition from Millipore or to the new version of the ERP system in a timely manner. If we do not have our own IT infrastructure, are unable to implement these transitions in a timely manner or if we do not have agreements with other providers of these services once our transitional services agreement with Millipore expires, we may not be able to effectively operate our business, and our profitability may decline.

Any failure or significant downtime in Millipore’s or our own information systems could prevent us from taking customer orders, shipping products or billing customers and could cause delays in production and delivery of our products and could harm our business and prospects. In addition, Millipore’s and our information systems require the services of employees with extensive knowledge of these information systems and the business environment in which we operate and we may be unable to attract and hire employees with the necessary skills to operate our information systems.

We currently use Millipore’s membrane manufacturing infrastructure, and our ability to meet our customer’s demands will suffer if we do not successfully transition our membrane manufacturing requirements to our own facilities.

We have entered into transition agreements with Millipore relating to the manufacture and distribution of specified products for limited periods of time. The manufacture of our membrane products is highly complex and requires sophisticated and costly equipment. While we are entitled to continue to manufacture membrane in Millipore’s plant until March of 2006, we might not be able to successfully transition the membrane production to a different facility after that date. As a result, any prolonged disruption in the operations of any of our

manufacturing facilities or any unforeseen delays in shifting membrane manufacturing operations to a new facility, whether due to technical or labor difficulties, destruction or damage to the facility or other reasons, could result in increased costs and reduced revenues and profitability and could harm our prospects.

Following our separation from Millipore, we do not have access to the research and development resources that were previously available to us, which could limit our research and development activities, thereby inhibiting our ability to develop new products in response to competitive pressures and harming our business and prospects.

Prior to our separation from Millipore, many research and development projects were conducted through the centralized Millipore research group. Following our separation from Millipore, while our research and development personnel have been transferred to us in accordance with the terms of the separation agreements, we do not have access to any other resources or personnel in Millipore’s research group other than in specific limited circumstances outlined in our research agreement with Millipore. As a result, we will not have access to all of the research and development facilities and resources that were previously available to us, and we may not be able to manage projects as successfully as we have in the past. If we are unable to continue to successfully develop new products and technology through internal research and development activities, we may not be able to maintain our market position or successfully grow our business and our business and prospects may be harmed.

Our agreements with Millipore limit our ability to use Millipore’s technology to fields of use in the microelectronics industry and may prevent us from expanding our business beyond the microelectronics industry.

Our use of Millipore’s technology is governed by the separation agreements, such as the master patent license agreement and the master trade secret and know-how agreement. The licenses granted by these agreements prohibit our use of Millipore’s technology in fields of use outside of the microelectronics industry. In general, where technology is used both by Millipore in the manufacture of its products and by us in the manufacture of our products, Millipore retained ownership of the technology and granted us a license to use the technology limited to fields of use in the microelectronics industry. In some cases, Millipore transferred ownership of the technology to us and retained an exclusive license to the technology in its fields of use in the biopharmaceutical and related industries. Under the master patent license agreement and the master trade secret and know-how agreement, we may sell products using Millipore’s technology only to customers in the microelectronics industry, as defined in the agreements, and we may not transfer the technology except in limited circumstances. These restrictions could limit our ability to expand our business into markets outside the microelectronics industry, which could limit our growth.

If the transitional services being provided to us by Millipore are not sufficient to meet our needs, or if we are not able to replace these services after our agreements with Millipore expire, we will be unable to manage critical operational functions of our business.

Pursuant to our separation from Millipore, Millipore agreed to provide transitional services to us. While many of these transitional service agreements have expired, transitional agreements continue with respect to the following services:

Although Millipore is contractually obligated to provide us with these services, these services may not be provided at the same level as when we were part of Millipore, and we may not be able to obtain the same benefits. These continuing transitional service arrangements generally have a term of five years following the separation. After the expiration of these various arrangements, we may not be able to replace the transitional services or enter into appropriate leases or other agreements in a timely manner or on terms and conditions, including cost, as favorable as those we will receive from Millipore. In particular, the manufacture of membranes involves the use of proprietary processes and equipment that belong to Millipore. As a result, after the expiration of the membrane manufacture agreement, we must acquire or design our own manufacturing equipment and develop our own processes to replace these proprietary processes and equipment.

These agreements were made in the context of a parent-subsidiary relationship and were negotiated in the overall context of our separation from Millipore. The prices charged to us under these agreements may be lower than the prices that we may be required to pay third parties for similar services or the costs of similar services if we undertake them ourselves and accordingly, following the expiration of our agreements with Millipore, our costs to procure these services may increase.

Our directors and executive officers may have conflicts of interest because of their ownership of Millipore common stock.

Many of our directors and executive officers have a substantial amount of their personal financial portfolios in Millipore common stock. Ownership of Millipore common stock by our directors and officers after our separation from Millipore could create, or appear to create, potential conflicts of interest when directors and officers are faced with decisions that could have different implications for Millipore and us.

We may have potential business conflicts of interest with Millipore with respect to our past and ongoing relationships.

Conflicts of interest may arise between Millipore and us in a number of areas relating to our past and ongoing relationships, including:

We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable because of our prior affiliation with Millipore and our continuing reliance on Millipore to provide transition services.

In addition, following our separation from Millipore, except as specifically prohibited in our separation agreements with Millipore with respect to the use of existing intellectual property and technological expertise, we may compete against Millipore and Millipore may compete against us. In particular, Millipore may choose to reestablish a microelectronics business unit, or work with a third party to establish a competitive capability.

Our ability to engage in acquisitions and other strategic transactions using our stock is subject to limitations because of the federal income tax requirements for a tax-free distribution.

In order for the distribution of our stock by Millipore to continue to qualify as tax-free to Millipore and its stockholders, there must not be a change in ownership of 50% or more in either the voting power or value of either our stock or Millipore’s stock that is considered to be part of a plan or a series of related transactions related to Millipore’s intended distribution of our stock to its stockholders. For this purpose, a change in ownership may include the issuance of our common stock or Millipore’s common stock in acquisitions and other similar strategic transactions or for compensation of employees and others. If there is a direct or indirect acquisition of our stock or Millipore’s stock by one or more persons during the four-year period beginning two years prior to and ending two years after the spin-out distribution of our shares, it will be presumed to be part of a plan or a series of related transactions related to Millipore’s intended distribution of our stock, and the distribution will be taxable to Millipore unless the presumption is successfully rebutted. The direct or indirect acquisition of our stock can include open market transactions. As a result, if within two years of the distribution any person or group of persons acting pursuant to a coordinated plan acquires 50% or more of our common stock, including through open market transactions, that is part of a plan or series of related transactions with the distribution by Millipore of our common stock, the distribution will be taxable to Millipore. Pursuant to our tax sharing agreement with Millipore, we may be responsible for the tax imposed on Millipore if the distribution fails to qualify as tax-free. For the above reasons, we are limited in our ability to use our stock for acquisitions and other similar strategic transactions or for compensation of employees and others. Many of our competitors have issued their stock to complete acquisitions, to expand their product offerings and speed the development of new technology, and to attract and retain employees and other key personnel. Therefore, these competitors may have a significant competitive advantage over us.

We may be responsible for income tax liabilities that relate to the distribution of shares of our common stock by Millipore and for other tax liabilities.

Millipore has received a tax ruling from the IRS to the effect that the distribution will qualify as a tax-free distribution for U.S. federal income tax purposes. The tax ruling is binding on the IRS, and can be relied upon by Millipore provided that the factual representations and assumptions made in Millipore’s request are true. We are not aware of any facts or circumstances that would cause such representations and assumptions to be untrue. Our tax sharing agreement with Millipore provides that we will be responsible for certain taxes imposed on Millipore, us or our respective subsidiaries if (i) we or one or more of our shareholders are responsible for the distribution’s failure to qualify for tax-free treatment, or (ii) the distribution of our shares subsequently becomes taxable to Millipore as a result of a change of ownership of 50% or more of the voting power or value of our stock. The process for determining whether a change of ownership has occurred under the tax rules is complex. If we do not carefully monitor our compliance with these rules we might inadvertently cause or permit a change of ownership to occur, triggering our obligation to indemnify Millipore pursuant to the tax sharing agreement. In addition, our obligation to indemnify Millipore in the event that a change of ownership causes the distribution not to be tax-free could discourage or prevent a third party from making a proposal to acquire our company. If the distribution by Millipore was determined to be taxable, the U.S. federal income tax payable by Millipore as a result of the distribution for which we have agreed to indemnify Millipore would be equal to 35% of the difference between the market value of the distributed stock on the date of the distribution and the tax basis of such stock. Assuming a market value of $10.50 per share for the distributed stock, the U.S. federal income tax payable by Millipore would equal approximately $63.5 million. If we were required to pay any of the taxes described above, the payment would significantly harm our business, financial position, results of operations and cash flow. In addition, under the tax sharing agreement that we entered into with Millipore, we are responsible for tax liabilities and adjustments to tax liabilities with respect to those Millipore foreign subsidiaries which we acquired pursuant to our separation from Millipore for periods prior to that separation. As we operate independently of Millipore we may adopt tax strategies different from those Millipore has followed which could impact our tax liability.

Our securities have had only a limited market, and we cannot assure you that our stock price will not decline.

There has been only a limited public market for our common stock, and an active public market for our common stock may not develop or be sustained after the distribution of our stock by Millipore to its shareholders. The market price of our common stock may be subject to significant fluctuations after this offering. Among the factors that could affect our stock price are:

The stock markets in general, and the markets for high technology stocks in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations may cause the trading price of our common stock to decrease.

We may not be able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 that we establish and maintain an adequate internal control structure for financial reporting, which could result in a loss of confidence in the reliability of our financial statements and decrease the value of your shares.

Section 404 of the Sarbanes-Oxley Act of 2002 requires the S.E.C. to adopt rules requiring public companies to include an “internal control” report in their annual reports on Form 10-K which contains an assessment by management of the effectiveness of the company’s internal control structure and procedures for financial reporting and to require the public accounting firm auditing the company’s financial statements to attest to and report on management’s assessment of the effectiveness of the company’s internal control structure and procedures for financial reporting. Until the S.E.C. issues rules there is uncertainty as to the specific standards that our internal control structure and procedures for financial reporting must meet. While we intend to conduct a rigorous review of our internal controls over financial reporting in order to assure compliance with the Section 404 requirements, there can be no assurance that our independent accountants will attest to our assessment. In the event that our independent accountants are not satisfied with the internal control structure and procedures for financial reporting that we develop or with the level at which it is documented, operated or reviewed they may decline to attest to management’s assessment. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements which could have a significant and adverse impact on the value of our shares.

Provisions in our charter documents, Delaware law, the Internal Revenue Code relating to Millipore’s distribution of our common stock and our shareholder rights plan may delay or prevent an acquisition of us, which could decrease the value of your shares.

Our certificate of incorporation and By-Laws, Delaware law and our shareholder rights plan contain provisions that could make it harder for a third party to acquire us without the consent of our board of directors. These provisions include a classified board of directors and limitations on actions by our stockholders by written consent. In addition, our board of directors has the right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer. Our shareholder rights plan will permit our stockholders to purchase shares of our common stock at a 50% discount upon the occurrence of specified events, including the acquisition by anyone of 15% or more of our common stock, unless such event is

approved by our board of directors. Delaware law also imposes restrictions on mergers and other business combinations between us and any holder of 15% or more of our outstanding common stock. Although we believe these provisions provide for an opportunity to receive a higher bid by requiring potential acquirers to negotiate with our board of directors, these provisions apply even if the offer may be considered beneficial by stockholders. If a change of control or change in management is delayed or prevented, the market price of our common stock could suffer. In addition, an acquisition or further issuance of our common stock could trigger the application of Section 355(e) of the Internal Revenue Code. Under the tax sharing agreement, we would be required to indemnify Millipore for the resulting tax and this indemnity obligation might discourage, delay or prevent a change of control that stockholders may consider favorable.

Your percentage ownership in us may be diluted by future issuances of capital stock, which could reduce your influence over matters on which stockholders vote.

Our board of directors has the authority, without action or vote of our stockholders, to issue all or any part of our authorized but unissued shares. These issuances would dilute your percentage ownership interest, which will have the effect of reducing your influence over matters on which our stockholders vote. In addition, if the issuances are made at prices that reflect a discount from the then current trading price of our common stock, your interest in the book value of our common stock might be diluted.

The information called for by this item is set forth under the heading “Market Risk” in Management’s Discussion and Analysis contained in Item 7 above which information is hereby incorporated by reference.

The information called for by this item is set forth in the Consolidated and Combined Financial Statements and Schedule Covered by the Report of Independent Accounts at the end of this report commencing at the pages indicated below:

All of the foregoing Consolidated and Combined Financial Statements and Schedule are hereby incorporated in this Item 8 by reference.

The information called for by this item with respect to registrant’s directors and compliance with Section 16(a) of the Securities Exchange Act of 1934 as amended is set forth under the caption “ Ownership of Mykrolis Stock” in Mykrolis’ definitive Proxy Statement for Mykrolis’ Annual Meeting of Stockholders to be held on April 24, 2003, and to be filed with the Securities and Exchange Commission on or about March 28, 2003, which information is hereby incorporated herein by reference.

Information called for by this item with respect to registrant’s executive officers is set forth under “Executive Officers of Mykrolis” in Item 1 of this report.

The information called for by this item is set forth under the caption “Management and Election Of Directors—Executive Compensation” in Mykrolis’ definitive Proxy Statement for Mykrolis’ Annual Meeting of Stockholders to be held on April 24, 2003, and to be filed with the Securities and Exchange Commission on or about March 28, 2003, which information is hereby incorporated herein by reference.

The following information is provided as of December 31, 2002, with respect to our compensation plans under which equity securities are authorized for issuance. The only equity securities that have been authorized for issuance under our compensation plans are options to acquire our common stock.

The information called for by Item 403 of Regulation S-K is set forth under the caption “Ownership Of Mykrolis Common Stock” in Mykrolis’ definitive Proxy Statement for Mykrolis’ Annual Meeting of Stockholders to be held April 24, 2003, and to be filed with the Securities and Exchange Commission on or about March 28, 2003, which information is hereby incorporated herein by reference.

The information called for by this item with respect to registrant’s directors relationships and related transactions is set forth under the caption “Management and Election of Directors—Nominees for Election as Directors” in Mykrolis’ definitive Proxy Statement for Mykrolis’ Annual Meeting of Stockholders to be held on April 24, 2003, and to be filed with the Securities and Exchange Commission on or about March 28, 2003, which information is hereby incorporated herein by reference.

The Company’s Chairman and Chief Executive Officer, C. William Zadel, and Chief Financial Officer, Bertrand Loy, evaluated the effectiveness of the Company’s Disclosure Controls and Procedures (as that term is defined in Rule 13a-14(c) under the Securities Exchange of 1934, as amended) as of February 14, 2003. Based on that evaluation, Messrs. Zadel and Loy concluded that the Company’s Disclosure Controls and Procedures were effective.

Since February 14, 2003 there have been no significant changes in the Company’s internal controls or in other factors that could significantly affect internal controls. No corrective actions with regard to significant deficiencies and material weaknesses were taken or required to be taken.

The Consolidated and Combined Financial Statements listed under Item 8 of this report and in the Index to Consolidated and Combined Financial Statements on page F-1 of this report which is incorporated by reference.

The Financial Statement Schedule listed under Item 8 of this report and in the Index to Consolidated and Combined Financial Statements on page F-1 of this report which is incorporated by reference.

B. The Company hereby files as exhibits to this Annual Report on Form 10-K the following documents:

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacity and on the dates indicated.

/s/ C. WILLIAM ZADEL

C. William Zadel,

Chairman and Chief Executive Officer

/s/ BERTRAND LOY

Bertrand Loy

Vice President and Chief Financial Officer

The accompanying notes are an integral part of the consolidated and combined financial statements

CONSOLIDATED AND COMBINED STATEMENTS OF SHAREHOLDERS’ EQUITY AND COMPREHENSIVE INCOME (LOSS)

The accompanying notes are an integral part of the consolidated and combined financial statements

A capital lease obligation of $234 was incurred when the Company entered into a lease for phone equipment in June 2002.

The accompanying notes are an integral part of the condensed consolidated and combined financial statements

On October 3, 2000, Millipore Corporation (“Millipore”) announced its plan to spin-off its microelectronics business, which served the semiconductor industry and certain related industries with products needed to manufacture semiconductor devices as well as a range of other products that now comprises Mykrolis Corporation (“the Company”). On October 16, 2000, the Company was incorporated in Delaware as a wholly owned subsidiary of Millipore to receive Millipore’s microelectronics business and to be the spun-off company. Prior to March 31, 2001, the Company’s business was operated as a fully integrated business unit of Millipore. On March 31, 2001, Millipore transferred to the Company substantially all of the assets and liabilities associated with its microelectronics business (the “Separation”). The Company completed its initial public offering (“IPO”) of 7.0 million shares of common stock on August 9, 2001 receiving net proceeds of approximately $94.0 million, after deducting underwriting commissions and offering expenses. The Company retained $75.0 million of the net proceeds and paid the balance to Millipore as repayment of amounts outstanding as intercompany loans incurred by the Company in connection with the Separation. After the initial public offering, Millipore owned 32.5 million shares or approximately 82.3% of the Company’s total outstanding common stock. On February 27, 2002 (the “Distribution Date”), Millipore completed the spin-off of the Company through the distribution to its shareholders of all of the 32.5 million shares of the Company’s common stock owned by Millipore on that date. Effective February 28, 2002 the Company is a fully independent company with 39.7 million shares of common stock outstanding at December 31, 2002.

The combined financial statements for periods prior to March 31, 2001 include amounts that have been derived from the consolidated financial statements and accounting records of Millipore using the historical results of operations and historical basis of assets and liabilities of the Company’s business. Management believes the assumptions underlying the combined financial statements are reasonable. However, the combined financial information included herein may not necessarily reflect the Company’s operating results, financial position and cash flows in the future or what they would have been had the Company been a separate, stand-alone entity during the periods presented. Because a direct ownership relationship did not exist among all the various units comprising the Company, Millipore’s net investment in the Company is shown as shareholders’ equity in the combined financial statements prior to the Separation. The Company began accumulating retained earnings (accumulated deficit) on April 1, 2001, following the effective date of the Separation, pursuant to which substantially all of the assets and liabilities of the Company’s business were transferred to the Company. Beginning April 1, 2001, the Company’s consolidated financial statements include all wholly-owned subsidiaries and assets and liabilities of the Company. All material intercompany transactions and balances between and among the Company’s subsidiaries have been eliminated.

Prior to March 31, 2001, Millipore allocated certain corporate expenses, including centralized research and development, legal, accounting, employee benefits, officers’ salaries, facilities, insurance, information technology services, distribution, treasury and other Millipore corporate and infrastructure costs. These expense allocations were determined on a basis that Millipore and the Company consider to be a reasonable assessment of the utilization of services provided or the benefit received by the Company. At the time of Separation from Millipore, the Company and Millipore entered into transition service agreements for Millipore to provide specified functions and for the Company to reimburse Millipore for the cost of providing these services. The agreements do not necessarily reflect the costs of obtaining the services from unrelated third parties or of the Company providing the applicable services itself. However, management believes that purchasing these services

from Millipore provides the Company with an efficient means of obtaining these services during the transition period. In addition, the Company has agreed to provide transition services to Millipore, for which the Company will be reimbursed at its cost.

Millipore used a centralized approach to cash management and the financing of its operations. Prior to the Separation, cash deposits from the Company were transferred to Millipore on a regular basis and netted against Millipore’s net investment. As a result, none of Millipore’s cash, cash equivalents or debt at the corporate level were allocated to the Company in the combined financial statements at December 31, 2000. Changes in Millipore’s net investment include net earnings of the Company plus net cash transfers to or from Millipore. After the Separation but prior to the IPO, the Company’s cash deposits were netted against the Separation Revolving Credit Agreement (see Note 15—Transactions with Millipore). From the IPO to Distribution Date, amounts due to Millipore were netted against amounts due from Millipore and reported as accounts payable-Millipore in the Company’s consolidated and combined financial statements. After Distribution Date, these transactions were reported as third party accounts payable and third party accounts receivable.

The consolidated and combined financial statements include the accounts of the Company. Intercompany balances and transactions have been eliminated. Investments in affiliated companies that are 20%–50% owned entities are accounted for under the equity method of accounting.

Certain reclassifications have been made to prior year statements to conform to the current year presentation.

The preparation of financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our judgments and estimates, including those related to revenues, accounts receivable, inventories, long-lived assets and goodwill, deferred tax assets, income tax contingencies, warranty obligations, restructuring charges, accrued pension and other post-retirement benefit obligations, and litigation contingencies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

Assets and liabilities of the Company’s foreign operations, for which the local currency is the functional currency, are translated into U.S. dollars at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at the average exchange rates prevailing during the year. The aggregate transaction gains and losses are included in the consolidated and combined statements of operations as a component of other income/(expense), net. Elements of invested equity are translated at historical rates. Foreign currency translation adjustments relating to invested equity of such operations are reported separately as a component of accumulated other comprehensive income (loss) as a component of shareholders’ equity.

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents are primarily comprised of money market funds. The carrying amounts approximate fair value due to the short maturities of these instruments.

The Company’s policy is to place its cash and cash equivalents with high quality financial institutions to limit the amount of credit exposure.

The Company has placed on deposit certain cash balances to secure facilities lease obligations. The Company classifies these cash balances as restricted cash.

The Company values its inventories at lower of cost or market on a first-in, first-out (FIFO) basis. Cost includes material, labor and applicable manufacturing overhead costs.

Reserves are provided for estimated excess and obsolete inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. The Company fully reserves for inventories deemed obsolete. Quarterly reviews of all inventory items are performed to identify excess and obsolete inventories on hand by comparing on-hand balances to recent historical usage as well as anticipated or forecasted demand, based upon input from sales, R&D and marketing functions. If estimates of demand diminish further or actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. The cost basis is adjusted of inventory that has been written down to reflect net realizable value.

Property, plant and equipment is recorded at cost. Expenditures for maintenance and repairs are charged to expense while the costs of significant improvements, which extend the life of the underlying asset, are capitalized. Assets are depreciated primarily using straight-line methods. Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation are eliminated and related gains or losses are reflected in income.

The estimated useful lives of the Company’s depreciable assets are as follows:

The Company periodically evaluates the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying value of an asset or class of assets may not be fully recoverable and exceeds its fair value. For long-lived assets the Company intends to hold and use, if the carrying amount of the asset exceeds the sum of undiscounted cash flows expected to result from the use of the asset over its useful life, an impairment loss will be recorded. The amount of the impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. Assets held for sale are valued at fair value less costs to sell the asset.

Goodwill represents the excess of the purchase price over the fair value of net tangible and identifiable intangible assets the Company has acquired and has accounted for under the purchase method in accordance with APB 16. The Company adopted the provisions of FAS 142 on January 1, 2002. Accordingly, the Company

ceased the ratable amortization of goodwill on that date. The Company performs an annual impairment test of its goodwill as required under the provisions of FAS 142. The Company believes that there has been no impairment of goodwill.

Other intangible assets consist primarily of patents, acquired technology, trade names and licenses. These assets are recorded at cost and amortized on a straight-line basis over periods ranging from 3 - 12 years.

Goodwill primarily resulted from the Company’s acquisition of Tylan General, Inc. in January 1997.

The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company provides a valuation allowance against net deferred tax assets if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Prior to Distribution, the Company’s results of operations have been included in Millipore’s consolidated income tax returns. Income tax expense (benefit) reported in the Company’s consolidated and combined statements of operations has been calculated on a separate tax return basis. Millipore managed its tax position for the benefit of its entire portfolio of businesses and its tax strategies are not necessarily reflective of the tax strategies that the Company would have followed as a separate stand-alone company.

Net sales consist of revenue from sales of products net of trade discounts and allowances. Revenue is recognized when evidence of an arrangement exists, contractual obligations have been satisfied, title and risk of loss have been transferred to the customer and collection of the resulting receivable is reasonably assured. In the event significant post-shipment obligations or uncertainties remain, revenue is deferred and recognized when such obligations are fulfilled by the Company or the uncertainties are resolved. The Company provides for estimated product returns under limited contractual obligations. Amounts billed to customers that relate to shipping costs are included in net sales and in cost of sales. Revenue from services is recognized when the services are provided. Our service revenue was less than 3.0% of total net sales for each of the three years ended December 2002, 2001 and 2000.

Other income (expense), net includes foreign currency transaction exchange gains and losses, income and losses on investments in 20% - 50% owned entities accounted for under the equity method and royalty income from Nihon Millipore (see Note 15—Transactions with Millipore). On a periodic basis, the recorded values of entities recorded under the equity method and other investments are reviewed to determine if impairment has taken place.

Basic earnings (loss) per share are calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share is based on the weighted average number of common shares and dilutive common equivalent shares assumed during the period,

calculated using the treasury stock method which determines of additional common shares that are issuable upon exercise of outstanding stock options. Shares used to compute diluted earnings (loss) per share exclude common share equivalents if their inclusion would have an anti-dilutive effect.

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of accounts receivable. The Company performs ongoing credit evaluations of its customers and generally does not require collateral. The Company’s customers are concentrated in the semiconductor industry, and relatively few customers account for a significant portion of the Company’s revenues. The Company regularly monitors the creditworthiness of its customers and believes that it has adequately provided for exposure to potential credit losses.

At the time revenue is recognized, the Company provides for estimated cost of product warranties as provided for under contractual arrangements. Warranty obligations are affected by product failure rates and service delivery costs incurred in correcting a product failure. Should such failure rates or costs differ from these estimates, accrued warranty costs would be adjusted in the period that such events or costs become known.

The Company’s employee stock compensation plans are accounted for in accordance with Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB 25”) and related interpretations. Under this method, no compensation expense is recognized as long as the exercise price equals or exceeds the market price of the underlying stock on the date of the grant. The Company elected the disclosure-only alternative permitted under Statement of Financial Accounting Standards No. 123, “Accounting for Stock-based Compensation” (FAS 123) and Statement of Financial Accounting Standards No. 148, “Accounting for Stock-Based Compensation—Transition and Disclosure” for fixed stock-based awards to employees.

At December 31, 2002 the Company has two stock-based employee compensation plans, which are described more fully in Note 11. The Company accounts for those plans under the recognition and measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations. No stock-based employee compensation cost is reflected in net income, as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of FASB Statement No. 123, Accounting for Stock-Based Compensation, to stock-based employee compensation.

Equity instruments issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete or a performance commitment date is reached.

Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss). The Company’s accumulated other comprehensive income (loss) shown on the consolidated and combined balance sheets consists of foreign currency translation adjustments which are not adjusted for income taxes since they relate to indefinite investments in non-U.S. operations.

During the fourth quarter of 2002, the Company recorded restructuring and other charges of $5,182 to further respond to the current semiconductor industry downturn. Of this amount, $1,683 relates to non-cash asset writedowns due to asset impairments. Key elements of these restructuring and other charges included:

During the third quarter of 2001, the Company recorded a restructuring charge of $4,922 in response to the prolonged duration and severity of the current semiconductor industry downturn. The restructuring charge included approximately $2,495 employee severance costs, a $726 write-off of leasehold improvements and $1,701 of net exit costs on leased property. Key initiatives included:

During the first quarter of 2001, the Company recorded restructuring and other charges of $12,566 in connection with its separation from Millipore to improve its manufacturing asset utilization and resize our overall cost structure. The restructuring and other charges included approximately $11,260 of employee severance costs resulting in the elimination of 205 positions worldwide, approximately $986 of equipment and leasehold improvements write-off and approximately $310 of lease cancellation costs. Key initiatives included:

During 2002, several changes to prior estimates occurred resulting in the reversal of $1,638 in employee severance costs and a $1,638 increase in leasehold and other costs. These changes in estimate are primarily due to the higher than expected level of attrition of 55 employees, lower than expected severance benefits paid and continued deterioration in the real estate market conditions. As of December 31, 2002, the accrued restructuring costs totaled $5,781. Of this amount, the majority of the $1,992 in severance costs for terminated employees will be paid in the first quarter of 2003. The facilities-related costs of $3,789 will be substantially paid by the fourth quarter of 2005.

The activity related to the Company’s restructuring accruals is shown below (in thousands):

The following table sets forth the computation of basic and diluted earnings (loss) per share for the year ended December 31, 2002, 2001 and 2000:

The loss on investment relates to the write-off of a cost method investment in a privately held company.

During 2002, the Company recorded an impairment charge of $971 on manufacturing machinery and decided to place a portion of the impaired manufacturing machinery up for sale. The equipment placed for sale was owned by the Company and placed with a subcontractor on its property for the machining of certain Mykrolis sub-components. Due to a permanent decline in business volume with this subcontractor, the machinery was recovered from the subcontractor. The value of this machinery was adjusted to its estimated fair market value. The $971 impairment loss was included as a component of “Cost of sales.”

The impairment was based upon the actual sale price of some of this machinery in 2002 and estimates of fair market value of similar machinery received from external independent equipment brokers. During 2002, $805 of the machinery held for sale was sold before December 31, 2002 and $338 remained in service. The $72 of unsold assets are included in assets held for sale in the consolidated balance sheet at December 31, 2002.

In June 2001, the Financial Accounting Standards Board (the “FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 142, Goodwill and Other Intangible Assets. Under the provisions of SFAS 142, goodwill and intangible assets with indefinite lives are not amortized, but tested for impairment annually or whenever there is an impairment indicator. In addition, upon adoption of SFAS 142, all goodwill must be assigned to reporting units for purposes of impairment testing and is no longer subject to amortization.

The Company adopted SFAS 142 as required on January 1, 2002. Accordingly, the Company performed an assessment of whether goodwill was impaired at the date of adoption and during the fourth quarter of 2002. The Company determined that for purposes of these assessments, the Company’s business consists of liquid products and gas products reporting units, and that the goodwill is attributable solely to the gas products reporting unit. The Company further estimated the gas products reporting unit’s fair value, as determined by an independent valuation service company, and compared it to the carrying value of the net assets of this reporting unit. As of January 1, 2002 and December 31, 2002, the gas reporting unit’s fair value exceeded the value of its net assets, and therefore goodwill was not impaired.

Goodwill amortization expense was $916 and $976 for the years ended December 31, 2001 and 2000, respectively. The Company estimates that goodwill amortization expense would have been approximately $916 for the year ended December 31, 2002. The following table presents a reconciliation of net loss and loss per share adjusted for the exclusion of goodwill (in thousands, except per share figures):

As of December 31, 2002, goodwill amounted to $14,454 net of accumulated amortization at December 31, 2002. Other identifiable intangible assets of $4,949 (net of accumulated amortization) at December 31, 2002 are being amortized over their estimated useful lives ranging from 5 to 15 years. The following table summarizes other intangible assets by major intangible asset class.

Total amortization expense for the year ended December 31, 2002 was $1,678. Estimated amortization expense for the fiscal years 2003 to 2006 is $1,505, $984, $936 and $815, respectively.

During the twelve months ended December 31, 2002 the Company was required to provide cash collateratization totaling $1,608 related to a security deposit under a new lease for its corporate headquarters, research and development and manufacturing facility and other security deposits. At December 31, 2002, this cash collateral was invested in U.S. federal agency securities and money market funds.

The Company’s income tax expense is summarized as follows for the year ended December 31:

A summary of the differences between the Company’s consolidated and combined effective tax rate and the United States statutory federal income tax rate is as follows:

Significant components of the Company’s deferred tax assets and liabilities are as follows:

At December 31, 2002, the Company has foreign tax credit carryforwards of approximately $581 that expire in 2006 to 2007, and general business tax credits of $288 that expire in 2016 to 2021. Net operating loss carryforwards of $57,519 expire in 2006 to 2022.

At December 31, 2001, the Company had a $9,000 income tax receivable related to net operating loss carrybacks determined on a separate return basis. In accordance with the tax sharing agreement, during the first quarter of 2002, Millipore decided not to allow the Company to carryback these net-operating losses. As a result, the receivable was transferred to Millipore during the first quarter of 2002 and is reflected in the consolidated financial statements as a reduction to additional paid in capital included in shareholders’ equity.

The valuation allowance is primarily recorded against foreign tax credits on unremitted earnings of the Company foreign subsidiaries of $18,262 and other U.S. deferred tax assets of $32,133 primarily attributable to net operating losses. The increase in the valuation allowance during 2002 is primarily recorded against net operating losses incurred during 2002. SFAS 109, “Accounting for Income Tax,” requires that the Company establish a valuation allowance when, based on an evaluation of objective verifiable evidence, the Company believes there is a likelihood that some portion or all of the deferred tax assets will not be realized. The Company records a valuation allowance for these tax assets based on management’s assessments of historical pre-tax income and of the significant deterioration in projected pre-tax income for early future periods given the uncertainty surrounding the prolonged cyclical downturn in the semiconductor industry.

During 2001, the Company adopted the 2001 Non-Employee Director Stock Option Plan (the “Directors Plan”) which was approved by the Company’s shareholders. The Directors Plan allows for the issuance of 250,000 shares of common stock. Under the Directors Plan, each Non-Employee Director is granted an option to purchase 10,000 shares of common stock upon initial election to the Board of Directors (or upon the Company’s initial public offering in the case of directors elected prior to that date) and each director is granted an option to purchase 5,000 shares of common stock on the anniversary date of his election. The exercise price of the stock options may not be less than the fair market value of the stock at the date of grant.

During 2002 the Directors Plan was amended to increase the number of options granted to each newly elected eligible director on the date of his or her first election from 10,000 in 2001 to 15,000. In addition, the number of options to be granted to each director annually was increased from 5,000 in 2001 to 10,000 and the annual grant date was changed to the date of the Annual Meeting of Stockholders.

During 2001, the Company adopted the 2001 Employee Stock Purchase Plan (“ESPP”) which was approved by the Company’s shareholders. The maximum number of shares which may be issued under the ESPP is 1,000,000 shares of authorized but unissued common stock. The ESPP allows eligible employees to purchase the stock at 85% of the lesser of the fair market value of the common stock on the Offering Date of such Offering Period, or the fair market value of the shares on the Purchase Date applicable to the shares being purchased during such Offering Period. Offering Periods consist of twenty-four month periods, commencing on April 1 and October 1 of each year and ending on the second March 31 and September 30, respectively, occurring thereafter. The first day of an Offering Period is the Offering Date. Each Offering Period consists of four consecutive Purchase Periods of six month duration. The last day of each Purchase Period is the Purchase Date for such Purchase Period.

During 2002, the ESPP also contained an initial transitional offering (the “Initial Plan Offering”) commencing November 1, 2001 and concluding on the later of March 31, 2002 or the third business day following the date of the distribution of the common stock of the Company by Millipore Corporation to its shareholders in accordance with the Master Separation and Distribution Agreement. The Offering Date for the Initial Plan Offering is the first day of the Initial Offering Period and the single Purchase Date for the Initial Plan Offering is the last day of the Initial Offering Period. All eligible employees are entitled to participate, and can purchase the stock at 85% of the lesser of the fair market value of the shares on the Offering Date of the Initial Plan Offering or the fair market value of the shares on the Purchase Date of the Initial Plan Offering.

Each employee may purchase up to 10% (up to a maximum of $25,000) of eligible compensation. 50,975 shares of common stock were issued under the ESPP as of December 31, 2002.

Prior to the Separation, employees of the Company were eligible to participate in the Millipore Employees’ Stock Purchase Plan (“Millipore ESPP”). The Millipore ESPP allowed eligible employees to purchase Millipore stock at 85% of the lesser of the fair market value of the common stock on June 1, the beginning of the plan year, or the closing price at the end of each subsequent quarter. Each employee could purchase up to 10% (up to a maximum of $25,000) of eligible compensation.

The Board of Directors of the Company adopted a shareholder rights plan (the “Rights Plan”) pursuant to which the Company declared a dividend on November 29, 2001 to its shareholders of record on December 31, 2001 of the right to purchase (a “Right”) one additional share of the Company’s common stock for each share of common stock owned, at a price of $130.00 for each share. The Rights Plan is designed to protect shareholders from attempts by others to acquire the Company on terms or by using tactics that could deny all shareholders the opportunity to realize the full value of their investment. The Rights are attached to the shares of our common stock until certain triggering events occur. The Rights authorize the holders to purchase shares of our common stock at a 50% discount from market value upon the occurrence of specified triggering events, including, unless approved by the board of directors, an acquisition by a person or group of specified levels of beneficial ownership of the Company’s common stock or a tender offer for the Company’s common stock. The common stock purchase rights are redeemable by us for $0.01 and will expire in March of 2011. One of the events which will trigger the common stock purchase rights is the acquisition, or commencement of a tender offer, by a person (an Acquiring Person, as defined in the shareholder rights plan), other than the Company or any subsidiaries of the Company or employee benefit plans, of 15% or more of the outstanding shares of our common stock. An acquiring person may not exercise a common stock purchase right. Until the Distribution of our shares, Millipore was excluded from the definition of acquiring person.

During 2001, the Company adopted the 2001 Equity Incentive Plan (the “2001 Plan”) as approved by the Company’s shareholders. The 2001 Plan provides for the issuance of stock-based and other incentive awards to selected employees, directors, and other persons (including both individuals and entities) who provide services to the Company or its Affiliates. The Board of Directors determines the term of each option, option price, number of shares for which each option is granted, whether restrictions will be imposed on the shares subject to options, and the rate at which each option is exercisable. The exercise price for incentive stock options may not be less than the fair market value per share of the underlying common stock on the date granted (110% of fair market value in the case of holders of more than 10% of the voting stock of the Company). The 2001 Plan contains an “evergreen” provision which increases the number of shares in the pool of options available for grant annually by 1% of the number of shares of common stock outstanding on the date of the Annual Meeting of Stockholders or such lesser amount determined by the Board of Directors.

Prior to the Separation date and in prior years, certain employees of the Company were granted stock options and restricted stock under Millipore’s stock-based compensation plan. The Millipore 1999 Stock Incentive Plan (the “Millipore Plan”) provided for the issuance of stock options and restricted stock to key employees as incentive compensation. The exercise price of a stock option was equal to the fair market value of Millipore’s common stock on the date the option was granted and its term was generally ten years and vested over four years. Unvested stock options outstanding under the Millipore Plan were converted to stock options of the Company at the Distribution. Effective February 28, 2002, these outstanding Millipore options were converted into options to purchase an aggregate of 2,914,313 shares of Mykrolis common stock at a weighted average exercise price of $7.76 share. Of these options, options to purchase an aggregate of 1,155,927 shares were fully vested and exercisable at December 31, 2002. The conversion of these stock options was done in such a manner that (1) the aggregate intrinsic value of the options immediately before and after the conversion was the same, (2) the ratio of the exercise price per option to the market value per option was not reduced, and (3) the vesting provisions and option period of the Company options were the same as the original vesting terms and option period of the Millipore options. None of these conversion options were issued from shares available for grant under the 2001 Plan.

The Millipore Plan also provided that the restricted stock, which is awarded to key members of senior management at no cost to them, cannot be sold, assigned, transferred or pledged during a restriction period which is normally four years but in some cases may be less. In most instances, shares are subject to forfeiture should employment terminate during the restriction period. The restricted stock is recorded at its fair market value on the award date and the related deferred compensation is amortized to selling, general and administrative expenses over the restriction period. The allocated portion of compensation expense attributable to the Company’s employees was $595 in 2001 and $1,177 in 2000. At December 31, 2001 and 2000, the Company’s employees held 26,182 and 55,500 shares of restricted stock; respectively and the related total deferred compensation included in the consolidated and combined statements of shareholders’ equity and total comprehensive income (loss) was $139 and $730, respectively. All of the restricted shares of Millipore held by the Company’s employees vested on February 11, 2002. This modification resulted in an additional compensation charge of $476 in 2002. During 2002 there was also an additional stock based compensation expense of $588 for the termination of two executives.

The following table summarizes information about stock options at December 31, 2002:

The Company applies the intrinsic value method prescribed by APB 25, in accounting for stock options granted to employees. Pro forma net earnings information as required by SFAS No. 123, “Accounting for Stock-Based Compensation,” has been determined as if the Company had accounted for employee stock options granted to the Company’s employees under SFAS No. 123’s fair value method. As described above, prior to the Separation date, certain employees of the Company were granted stock options under Millipore’s stock-based compensation plan. During 2001, the Company adopted its own plan, which provides for the issuance of stock-based awards to employees, directors, and other persons who provide services to the Company or its affiliates. The fair value of options granted under both the Company’s and Millipore’s stock-based plan were estimated at grant date using a Black-Scholes option pricing model with the following weighted-average assumptions:

The pro-forma expense amounts assume that the fair value assigned to the option grants was amortized over the vesting period of the options, which ranges from one to four years for the Company’s plan and four years for the Millipore plan, while the fair value assigned to grants under the stock purchase plan is recognized in full at the date of grant. The pro forma effect on reported net income (loss) and earnings (loss) per share of recognizing compensation expense in accordance with SFAS No. 123 would have been as follows.

The weighted average estimated fair value of stock options granted during the years ended December 31, 2002 and 2001 was $5.13 per share and $8.52 per share, respectively.

At the Distribution date, the Company assumed responsibility for certain of the pension benefits and the other post-retirement benefits for employees whose last work assignment prior to the Distribution was with the Company. These employees are collectively referred to as “Mykrolis Employees.” The pension liabilities that have been assumed by the Company and the liabilities related to the other post-retirement benefits as well as the related expenses have been reflected in the consolidated and combined financial statements for all years presented.

Prior to the Separation, the U.S. employees of the Company participated in Millipore’s non-contributory defined benefit pension plan, which covered substantially all U.S. employees. The Mykrolis Employees maintained their vested and unvested rights in the Millipore pension plans after the Separation date. However, the liabilities related to these rights were not assumed by the Company and therefore are not reflected in the consolidated and combined balance sheets of the Company. Millipore allocated to the Company net periodic pension costs related to Mykrolis employees that participated in this plan. No contribution was required for 2002, 2001 or 2000, as the plan was adequately funded.

The majority of the Company’s U.S. employees are covered under the Mykrolis Corporation Savings and Investment Plan (the “Savings and Investment Plan”), that was adopted by the Company in March 2001. The Savings and Investment Plan allows employees to make certain tax-deferred voluntary contributions upon hire date. Mykrolis currently matches 50% of participant contributions, up to a maximum of 6% of the participant’s compensation. Millipore had a similar plan prior to the Separation date where Millipore matched 25% of certain tax-deferred voluntary contributions after one year of service. The Savings and Investment Plan also has a discretionary contribution component whereby Mykrolis can make a contribution as determined by its Board of Directors.

Prior to April 1, 2001, all U.S. employees of the Company are covered under the Millipore Corporation Participation Plan (the “Participation Plan”), which is a defined contribution plan. Contributions to the Millipore Participation Plan are allocated among the U.S. employees of the Company who have completed at least two years of continuous service on the basis of the compensation they received during the year for which the contribution is made.

The total combined expenses under the Savings and Investment Plan and Participation Plan was $2,407 in 2002, $2,198 in 2001 and $2,972 in 2000.

Mykrolis offers a Supplemental Savings and Retirement Plan (the “Supplemental Plan”) to certain senior executives that allows certain salary deferral benefits that would otherwise be lost by reason of restrictions imposed by the Internal Revenue Code limiting the amount of compensation which may be deferred under tax-qualified plans. The liabilities related to these rights were assumed by the Company at the Separation, and are therefore reflected in the consolidated and combined balance sheets. During 2002 and 2001, the Company’s expense was $20 and $48, respectively. Millipore had a similar plan prior to the Separation, of which the Company’s expense was $190 in 2000.

The employees of the Company’s subsidiary in Japan (“Nihon Mykrolis”) are covered by a defined benefit pension plan. Substantially all the Company’s U.S. employees are covered under several unfunded defined benefit post-retirement benefit plans, which are sponsored by Mykrolis. The plans provide medical and life insurance benefits and are, depending on the plan, either contributory or non-contributory.

The tables below set forth the estimated net periodic cost and funded status of the Nihon Mykrolis Pension Plan and the U.S. Post-Retirement Benefit Plan.

For postretirement healthcare, a 10.0% annual rate of increase in the per capita cost of covered health care benefits was assumed for fiscal year 2002. The rate was assumed to decline gradually to 5.0% by 2009, and remain at that level thereafter.

Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans. A one-percentage-point change in the assumed health care cost trend rates would have the following effects.

The Company has one reportable segment that develops, manufactures and sells consumables and capital equipment to semiconductor fabrication companies and other companies using similar manufacturing processes, as well as OEM suppliers to those companies. The Company also provides capital equipment warranty and repair services to customers in this segment. The Company’s products include membrane and metal based filters, housings, precision liquid dispense filtration pumps, resin based gas purifiers and mass flow and pressure controllers. The products are used by customers in manufacturing operations to remove contaminants in liquid and gas processes, to purify liquids and gases, to measure and control flow rates and to control and monitor pressure and vacuum levels during the manufacturing process. The Company’s products are sold worldwide through a direct sales force and through distributors in selected regions.

The Company attributes net sales and long-lived assets to different geographic areas on the basis of the location of the customer. Net sales for each of the years ended December 31, 2002, 2001 and 2000 along with long-lived asset information as of December 31, 2002 and 2001 by geographic area in U.S. dollars is presented as follows:

Historically, the Company has relied on a limited number of customers for a substantial portion of its net sales. During the fiscal years ended December 31, 2002, 2001 and 2000 revenues from one customer represented 13%, 14% and 18%, respectively of total net sales. Accounts receivable for this customer was approximately

$3,843, $2,686 and $10,300 at December 31, 2002, 2001 and 2000, respectively. There were no other customers that accounted for more than 10% of revenues or accounts receivable during any of these years.

For purposes of governing certain of the ongoing relationships between the Company and Millipore at and after the Separation and to provide for an orderly transition, the Company and Millipore entered into various agreements at the Separation date. A brief description of each of the agreements follows.

The separation agreement contains the key provisions relating to the Separation, the Company’s initial funding, initial public offering and the Distribution. The agreement lists the documents and items that the parties delivered in order to accomplish the transfer of assets and liabilities from Millipore to the Company, effective on the Separation date. The parties also entered into ongoing covenants that survive the transactions, including covenants to establish interim service level agreements, exchange information, notify each other of changes in their accounting principles and resolve disputes in particular ways.

The General Assignment and Assumption Agreement identifies the assets that Millipore transferred to the Company and the liabilities that the Company assumed from Millipore in the Separation. In general, the assets transferred and the liabilities assumed are those that appear on the combined balance sheet, after adjustment for certain assets and liabilities that were retained by Millipore and for activity that occurs between the balance sheet date and the Separation.

The Separation Revolving Credit Agreement (the “Credit Agreement”) provided for Millipore to lend the Company funds between the Separation date and the date of the IPO in order to fund the Company’s working capital needs and to settle any amounts payable by the Company related to the retention by Millipore of specified assets and liabilities of the Company and the retention by the Company of specified Millipore assets and liabilities that could not be transferred at the Separation due to restrictions imposed by foreign laws or because such transfer was not practical. The net outstanding balance of $27,512 was paid to Millipore pursuant to the terms of this Credit Agreement from proceeds generated from the IPO and cash generated from operations between the Separation date and the IPO date. There was no interest expense associated with the Credit Agreement.

The Separation Note provided for a payment by the Company to Millipore out of the proceeds from the IPO. Millipore contributed its microelectronics business to the Company in exchange for shares of the Company’s common stock plus the Separation Note. The amount of the Separation Note was determined by agreement between Millipore and the Company to ensure that all net proceeds of the IPO in excess of $75,000 would be payable to Millipore. The principal balance of the Separation Note was calculated by deducting from the net IPO proceeds (i) the outstanding balance under the Credit Agreement as described above, and (ii) the $75,000 retained by the Company for general corporate purposes from the IPO proceeds. As a result, $19,095 was paid to Millipore as payment of the Separation Note. There was no interest expense associated with this note.

The Master Transitional Services Agreement governs the terms and conditions upon which interim transitional services are provided to each of the Company and Millipore. These services include facilities, engineering, information technology, equipment usage, financial accounting, distribution and warehousing and human resources administration. The Company and Millipore will also provide each other additional services as the Company and Millipore may identify from time to time after the Separation. Specific charges for such services are generally intended to allow the Company providing the service to recover direct costs plus expenses, without profit.

The Membrane Manufacture and Supply Agreement enables the Company to manufacture certain membranes in the same production areas and with the same processes as were available to the Company prior to the Separation for both its own use and sale. Under the agreement, Millipore leases this space and manufacturing equipment to the Company for five years. This agreement also provides for the supply of certain membranes manufactured by either the Company or Millipore to the other party at costs appropriate to that of a third party contract manufacturer.

The Company and Millipore have historically sold products of the other company within their respective fields of use. The Product Distribution Agreement allows each company to purchase products from the other company at prices representing discounts off published list prices.

The Research Agreement defines specific research projects that Millipore will perform for the Company on a contract basis and the process for conducting such research.

The Employee Matters Agreement outlines how Millipore and the Company allocate responsibility for and liability related to the employment of those employees of Millipore who became the Company’s employees. The agreement also contains provisions describing the Company’s benefit and equity plans. On or before the Distribution, the Company established employee benefit plans comparable to those of Millipore for its active, inactive and former employees. However, in certain cases, certain of its employees will continue to participate in the Millipore benefit plans. The transfer to the Company of employees at certain of Millipore’s international operations, and of certain pension and employee benefit plans, may not take place until the Company receives consents or approvals or has satisfied other applicable requirements.

The Millipore Contract Manufacturing Agreement provides for Millipore to manufacture certain products for resale by the Company at prices subject to annual increases equal to actual increases in Millipore’s cost to manufacture these products. There are no minimum or maximum purchase requirements, subject to binding three-month forecasts that may increase or decrease by 25% without penalty. The Company may not resell these products into Millipore’s biopharmaceutical business. This agreement has a term of five years, unless terminated by the Company on sixty days prior written notice. The Company has also agreed to manufacture parts for Millipore for use in Millipore’s products on substantially similar terms pursuant to the Mykrolis Contract Manufacturing Agreement.

This plan sets forth the steps and actions to be taken in order to separate the Company’s business conducted outside of the U.S. from the bioscience businesses conducted outside the U.S. and being retained by Millipore. It details the legal entity structure for the Company and the actions being taken to transfer employees, assets and operations to these legal entities in compliance with local laws and regulations.

The Company and Millipore entered into a Tax Sharing Agreement, which governs the Company’s and Millipore’s respective rights, responsibilities and obligations after the Distribution with respect to taxes for the periods ending on or before the Distribution. In addition, the Tax Sharing Agreement provides a basis to allocate any liability for taxes that are incurred as a result of the restructuring activities undertaken to implement the Separation. If the Distribution fails to qualify as a tax-free distribution under Section 355 of the Internal Revenue Code because of the acquisition of the Company’s stock or assets, or some other actions of the Company, then the Company will be solely liable for any resulting corporate taxes. Generally, Millipore indemnifies the Company for any tax liability resulting from adjustments due to an amended return, claim for refund or a tax audit, relating to Millipore or any domestic subsidiary for periods prior to Separation. However, the Company is responsible for tax liabilities of Millipore foreign subsidiaries that were transferred to the Company in the Separation for periods prior to the Separation.

Under the intellectual property agreements, Millipore transferred to the Company its rights in specified patents, specified trademarks and other intellectual property related to the Company’s current business and research and development efforts. Millipore and the Company will each license the other under selected patents and other intellectual property the right to use those patents and other intellectual property in their respective businesses, subject to field of use restrictions. Millipore and the Company each have an option, exercisable within the first five years of the agreements, to be licensed under specified patents of the other issued on patent applications with effective filing dates before the Separation date, subject to field of use restrictions and the payment of a royalty. The Company was also assigned know-how that is used in the manufacture of its products as of the Separation date. The agreements include certain rights to sublicense for both parties. The Company is licensed to use the Millipore trademark for up to three years with certain field of use limitations.

During 2001, Mykrolis entered into a royalty agreement with Nihon Millipore, which provides Nihon Millipore the right to use certain intellectual property that was developed by Mykrolis in connection with the bioscience business. As a result of this agreement, $553 and $605 in royalty income from Millipore was recognized and recorded in other income (expense), net for the years ended December 31, 2002 and 2001, respectively.

For the years ended December 31, 2002, 2001 and 2000 the Company purchased products from Millipore for inclusion in its products sold to third parties totaling $2,717, $2,955 and $3,949 respectively. Products sold to Millipore totaled $2,010 and $1,593 for the years ended December 31, 2002 and 2001, respectively and were not material for the year ended December 31, 2000.

For the year ended December 31, 2002 and the nine months from the Separation on April 1, 2001 through December 31, 2001, services purchased under the transition service agreements between Millipore and the Company are as follows.

For the year ended December 31, 2002 and the nine months from the Separation on April 1, 2001 through December 31, 2001, services provided to Millipore related to manufacturing, distribution, research and development and management are presented below and include sublease income from Millipore for manufacturing space they occupy in the Company’s Yonezawa, Japan facility of $704 and $563 for the years ended December 31, 2002 and 2001, respectively. These costs provided to Millipore are reductions to operating expenses in the Company’s consolidated and combined financial statements.

In addition, prior to the Separation on March 31, 2001, the Company’s combined financial statements include costs and expenses allocated from Millipore for centralized research and development, legal, accounting, employee benefits, officers’ salaries, facilities, insurance, information technology services, distribution, treasury and other Millipore corporate and infrastructure costs. These allocations were determined on bases that Millipore and the Company considered to be a reasonable assessment of the utilization of services provided or the benefit received by the Company. The allocation methods included relative sales, headcount, square footage and specific identification. Allocated costs included in the accompanying consolidated and combined statements of operations are presented below.

After the Separation from Millipore, any changes to the Company’s April 1, 2001 balance sheet were made through additional paid in capital included in shareholders’ equity. During 2002, these transfers primarily consist of the $9,000 income tax receivable described in Note 10 above as well as fixed asset adjustments. During 2001, these transfers mainly relate to accrued liabilities.

As described in Note 1, prior to the Separation on March 31, 2001, changes in Millipore’s net investment included, net earnings (losses) of the Company and net transfers (to)/from Millipore. Components of the net transfers are as follows:

Cash transfers to Millipore relate primarily to cash collected on accounts receivable that are transferred to the Millipore centralized cash management account prior to March 31, 2001. In addition, cash transfers from Millipore relate to direct operating costs, capital expenditures and income taxes paid by Millipore on the Company’s behalf. Allocated costs represent the Company’s share of allocated costs incurred and paid by Millipore prior to March 31, 2001.

The annual average of Millipore’s net investment in the Company was $223,566 for the year ended December 31, 2000.

In 1999, Millipore made a loan to an executive officer of the Company, which was collateralized by real estate held by the executive. During 2001, the loan was fully paid. The loan receivable of $450 was included in other assets in the consolidated and combined balance sheet at December 31, 2000.

The Company’s capital and operating lease agreements cover sales offices, manufacturing, information technology equipment and warehouse space. These leases have expiration dates through 2014. Certain land and building leases contain renewal options for periods ranging from one to five years and purchase options at fair market value. As of April 1, 2002 the Company entered into a 12-year lease for its new corporate headquarters, research and development and manufacturing facility. Annual rental payments under the lease are $2,451 for the first six years and $2,801 for the remaining six years plus basic operating costs and real estate taxes. Upon execution of the lease, the Company was required to issue an irrevocable standby letter of credit in the initial amount of $1,000 to be reduced by $125 on each of the first six anniversaries of commencement of the lease. This lease also provides the Company with two 5-year renewal options at market rent. Under the lease terms relating to the Company’s Bedford, Massachusetts facility, the Company has an option to purchase the facility at fair market value between June 2005 and November 2005, the expiration date of the lease, and the lessor has the option to sell the facility to the Company at 90% of the then current fair market value prior to November 2005. Rental expense was $8,738 in 2002, $7,425 in 2001 and $6,775 in 2000. The 2002 and 2001 rental expense includes $1,164 and $2,876 respectively, of transitional service agreement costs associated with the sharing of space owned by Millipore. The Company leases space in its Tokyo, Japan office to Millipore for research and development activities. This lease is renewed at each one year anniversary of the Distribution date unless either party proposes to terminate the lease at least twelve months before expiring. Millipore leases space in Bedford,

MA to the Company for the manufacturing of membrane which continues to March 2006. During 2002, the Company relocated the Jaffrey, NH manufacturing operation and the Bedford, MA headquarters to a single Billerica, MA facility. At December 31, 2002, future minimum rents payable under noncancelable leases with initial terms exceeding one year were as follows:

The Company is subject to other claims and legal proceedings which, in the opinion of the Company’s management, are incidental to the Company’s normal business operations. In the opinion of the Company, although final settlement of these suits and claims may impact the Company’s financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, results of operations or cash flows.

The Company’s product warranty liability for the 2002 year is summarized below.

The Company adopted Financial Accounting Standards Board (the “FASB”) Statement of Financial Accounting Standards (“SFAS”) No. 142 as required on January 1, 2002. The Company performed an assessment of whether there was an indication that goodwill was impaired at the date of adoption. It was determined that, for purposes of this, the Company’s business consists of liquid products and gas products reporting units and that goodwill is attributable solely to the gas products reporting unit. The Company has estimated the gas products reporting unit’s fair value, as determined by an independent valuation services company and compared it to the carrying value of the net assets of this reporting unit. As of January 1, 2002 and December 31, 2002, the gas reporting unit’s fair value exceeded its value of the net assets, and therefore goodwill was not impaired. Goodwill amortization expense was $0.9 million and $1.0 million for the years ended December 31, 2001 and 2000,

respectively. As a result of the adoption of SFAS 142, goodwill amortization ceased effective January 1, 2002. Goodwill amortization expense would have been approximately $0.9 million for the year ended December 31, 2002.

In August 2001, the FASB issued Statement No. 143, “Accounting for Asset Retirement Obligations” (“SFAS 143”), which provides the accounting requirements for retirement obligations associated with tangible long–lived assets. This Statement requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred. This Statement is effective for the Company’s 2003 fiscal year, and early adoption is permitted. The adoption of SFAS 143 is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows.

In October 2001, the FASB issued Statement of Financial Accounting Standards No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets” (“SFAS 144”). The objectives of SFAS 144 are to address significant issues relating to the implementation of FASB Statement 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of” (“SFAS 121”) and to develop a single accounting model, based on the framework established in SFAS 121, for long-lived assets to be disposed of by sale, whether previously held and used or newly acquired. SFAS 144 is effective for financial statements issued for fiscal years beginning after December 15, 2001, and generally, its provisions are to be applied prospectively. We adopted this standard effective January 1, 2002.

In June 2002, the FASB issues Statement of Financial Accounting Standards No. 146, “Accounting for Exit or Disposal Activities” (“SFAS 146”). SFAS 146 addresses significant issues regarding the recognition, measurement and reporting of costs that are associated with exit and disposal activities, including restructuring activities that are currently accounted for under Emerging Issues Task Force No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit and Activity (including Certain Costs Incurred in a Restructuring)” (“EITF 94-3”). The scope of SFAS 146 also includes costs related to terminating a contract that is not a capital lease and termination benefits that employees who are involuntarily terminated receive under the terns of a one-time benefit arrangement that is not an ongoing benefit arrangement or an individual deferred compensation contract. We are required to adopt the provisions of SFAS 146 effective for exit or disposal activities initiated after December 31, 2002. The provisions of EITF 94-3 shall continue to apply for any exit activity initiated under an exit plan that met the criteria of EITF 94-3 prior to adoption of SFAS 146. The adoption of SFAS 146 will change, on a prospective basis, the timing of recording restructuring charges from the commitment date to when the liability is incurred. The adoption of the standard will impact the timing of recording of restructuring activities initiated subsequent to December 31, 2002.

In December 2002, the FASB issued Statement of Financial Accounting Standards No. 148 (“SFAS 148”), “Accounting for Stock-Based Compensation—Transition and Disclosure—an Amendment of FASB Statement No. 123” (“SFAS 123”), which is effective for financial statements for fiscal years ending after December 15, 2002, with early adoption permitted. SFAS 148 will enable companies that choose to adopt the preferable fair value method to report the full effect of employee stock options in their financial statements immediately upon adoption, and to make available to investors better and more frequent disclosure about the cost of employee stock options. We will continue to apply the disclosure only provisions of both SFAS 123 and SFAS 148.

the obligation undertaken in issuing the guarantee. The initial recognition and initial measurement provisions of FIN No. 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002. The disclosure requirements of FIN No. 45 are applicable for financial statements of interim periods ending after December 15, 2002 and are included in Note 16 to the condensed consolidated and combined financial statements.

In November 2002, the EITF issued No. 00-21, “Accounting for Revenue Arrangements with Multiple Deliverables.” EITF No. 00-21 addresses certain aspects of the accounting by a vendor for arrangements under which it will perform multiple revenue-generating activities. EITF No. 00-21 establishes three principles: revenue should be recognized separately for separate units of accounting, revenue for a separate unit of accounting should be recognized only when the arrangement consideration is reliably measurable and the earnings process is substantially complete, and consideration should be allocated among the separate units of accounting in an arrangement based on their fair values. EITF No. 00-21 is effective for all revenue arrangements entered into in fiscal periods beginning after June 15, 2003, with early adoption permitted. The Company is evaluating the impact, if any, that this pronouncement will have on the consolidated financial statements.

In January 2003, the FASB issued FIN No. 46 “Consolidation of Variable Interest Entities, an interpretation of ARB 51.” FIN 46 provides guidance on the identification of entities for which control is achieved through means other than through voting rights called “variable interest entities” or “VIEs” and how to determine when and which business enterprise should consolidate the VIE (the “primary beneficiary”). This new model for consolidation applies to an entity which either (1) the equity investors (if any) do not have a controlling financial interest or (2) the equity investment at risk is insufficient to finance that entity’s activities without receiving additional subordinated financial support from other parties. In addition, FIN 46 requires that both the primary beneficiary and all other enterprises with a significant variable interest in a VIE make additional disclosures. Certain transitional disclosures are required in financial statements initially issued after January 31, 2003, if it is reasonably possible that once this guidance is effective the enterprise will either be required to consolidate a variable interest entity or will hold a significant variable interest in a variable interest entity. The Company does not believe that it has any interests that would change our current reporting entity or require additional disclosures outlined in FIN 46.

In January 2003, the Company sold the remaining surplus machinery for cash proceeds of $73.

In our opinion, the consolidated and combined financial statements listed in the accompanying index present fairly, in all material respects, the financial position of Mykrolis Corporation and its subsidiaries (the “Company”), formerly a majority-owned subsidiary of Millipore Corporation (“Millipore”), at December 31, 2002 and 2001, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2002 in conformity with accounting principles generally accepted in the United States of America. In addition, in our opinion, the financial statement schedule listed in the accompanying index presents fairly, in all material respects, the information set forth there in when read in conjunction with the related consolidated and combined financial statements. These financial statements and the financial statement schedule are the responsibility of the Company’s management; our responsibility is to express an opinion on these financial statements and the financial statement schedule based on our audits. We conducted our audits of these statements in accordance with auditing standards generally accepted in the United States of America, which require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

The Company was comprised of Millipore’s microelectronics business which was historically integrated with the businesses of Millipore; consequently, as indicated in Note 1, the financial statements as of December 31, 2001 and for the years ended December 31, 2001 and 2000 have been derived from the consolidated financial statements and accounting records of Millipore, and reflect significant assumptions and allocations. Moreover, as indicated in Note 1, the Company relies on Millipore for administrative, management, research and other services. Accordingly, these consolidated and combined financial statements do not necessarily reflect the financial position, results of operations, and cash flows of the Company had it been a stand-alone company.

We have experienced, and expect to continue to experience, significant fluctuations in our quarterly results. Our expense levels are based, in part, on expectations of future revenues. If revenue levels in a particular quarter do not meet expectations, operating results are adversely affected. The following table sets forth our unaudited operating results for our last eight quarters. The information has been derived from our unaudited consolidated and combined financial statements that, in our opinion, reflect all normal, recurring adjustments necessary for a fair presentation. The operating results for any quarter are not necessarily indicative of results for any future period.

The following table sets forth our financial information stated as a percentage of net sales for the past eight quarterly periods:

Delaware		04-3536767
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

129 Concord Road, Billerica, MA		01821
(Address of principal executive offices)		(Zip Code)

Title of Class		Name of Exchange on Which Registered
Common Stock, $0.01 Par Value		New York Stock Exchange, Inc.

Document		Incorporated into Form 10-K
Definitive Proxy Statement, dated March 28, 2003		Part III

• historical customer relationships;		• breadth of product line;

• technical expertise;		• breadth of geographic presence;

• product quality and performance;		• manufacturing capabilities; and

• total cost of ownership;		• after-sales service.

• customer service and support;

Location	Principal Function	Approximate Square Feet		Leased/ Owned
Billerica, Massachusetts	Executive Offices, Research & Manufacturing	175,000		Leased
Allen, Texas	Research & Manufacturing	178,000		Leased
Yonezawa, Japan	Manufacturing	132,000	(1)	Owned

Name	Age	Office	First Elected To Office
Corporate Officers
C. William Zadel	59	Chairman of the Board, and Chief Executive Officer	2001
Jean-Marc Pandraud	50	President and Chief Operating Officer	2001
Bertrand Loy	37	Vice President, Treasurer and Chief Financial Officer	2001
Peter W. Walcott	56	Vice President, Secretary & General Counsel	2001
Fred E. Faulkner, Jr.	56	Vice President—Worldwide Manufacturing	2001
Takashi Mizuno	43	Vice President; President Nihon Mykrolis KK	2001
Robert Crook	49	Vice President—Human Resources	2001
Other Executive Officers
Gerry Mackay	40	Vice President; Worldwide Sales and Marketing	2002
Jieh-Hwa Shyu	49	Vice President—R & D	2001

	Range of Stock Prices								Dividends Declared
	2002				2001(1)				2002		2001
	High		Low		High		Low		(Per Share)
First Quarter	$	16.01	$	9.55		N/A		N/A	$	0.00	$	0.00
Second Quarter	$	18.15	$	10.44		N/A		N/A	$	0.00	$	0.00
Third Quarter	$	12.08	$	5.80	$	16.25	$	8.97	$	0.00	$	0.00
Fourth Quarter	$	8.90	$	3.18	$	16.00	$	7.51	$	0.00	$	0.00	(2)

	2002			2001			2000			1999			1998
	(In thousands, except per share data)
Statement of Operations Data:
Net sales	$	178,449		$	215,274		$	355,540		$	206,345		$	180,613
Cost of sales		118,783			137,621			174,545			107,154			120,147

Gross profit		59,666			77,653			180,995			99,191			60,466
Selling, general and administrative expenses		67,809			80,724			96,469			75,052			70,400
Research and development expenses		19,685			19,837			23,175			19,309			21,492
Restructuring and other charges		5,182			17,478			(320	)		(1,221	)		7,120
Litigation settlement		—			—			—			—			3,666

Operating income (loss)		(33,010	)		(40,386	)		61,671			6,051			(42,212	)
Other income (expense), net		3,367			(1,096	)		(1,395	)		(83	)		(823	)

Income (loss) before income taxes		(29,643	)		(41,482	)		60,276			5,968			(43,035	)
Income tax expense (benefit)		2,118			26,145			22,905			2,685			(15,923	)

Net income (loss)	$	(31,761	)	$	(67,627	)	$	37,371		$	3,283		$	(27,112	)

Basic and diluted earnings (loss) per share	$	(0.80	)	$	(1.92	)	$	1.15		$	0.10		$	(0.83	)
Shares used in computing basic and diluted earnings (loss) per share		39,628			35,262			32,500			32,500			32,500

	December 31,
	2002		2001		2000		1999		1998
	(In thousands)
Balance Sheet Data:
Working capital (1)	$	116,285	$	153,526	$	130,037	$	78,055	$	41,794
Total assets		267,189		289,490		299,031		244,507		219,126
Millipore’s invested equity		—		—		246,489		197,658		182,353
Shareholders’ equity		212,644		243,547		—		—		—

	Year Ended December 31,
	2002		2001		2000
	(In millions)
Cost of sales	$	3.9	$	5.5	$	6.0
Selling, general and administrative expenses		3.1		11.0		33.8
Research and development expenses		0.6		1.8		2.3

Total	$	7.6	$	18.3	$	42.1

	Year Ended December 31,									Year Ended December 31,
	2002			2001			2000			2002		2001		2000
	(In millions)									(As a percent of net sales)
Net sales	$	178.4		$	215.3		$	355.5		100.0	%	100.0	%	100.0	%
Cost of sales		118.8			137.6			174.6		66.6		63.9		49.1

Gross profit		59.6			77.7			180.9		33.4		36.1		50.9
Selling, general and administrative expenses		67.8			80.7			96.4		38.0		37.5		27.1
Research and development expenses		19.7			19.8			23.1		11.0		9.2		6.5
Restructuring and other charges		5.2			17.5			(0.3	)	2.9		8.1		(0.1	)

Operating income (loss)		(33.1	)		(40.3	)		61.7		(18.5	)	(18.7	)	17.4
Other income(expense), net		3.4			(1.1	)		(1.4	)	1.9		(0.5	)	(0.4	)

Income (loss) before income taxes		(29.7	)		(41.4	)		60.3		(16.6	)	(19.2	)	17.0
Income tax expense		2.1			26.2			22.9		1.2		12.2		6.4

Net income (loss)	$	(31.8	)	$	(67.6	)	$	37.4		(17.8	)%	(31.4	)%	10.5	%

	Net Sales in US Dollars						Net Sales by Geographic Region
	2002		2001		2000		2002		2001		2000
	(In millions)						(As a percentage of net sales)
North America	$	55.3	$	70.4	$	138.0	31.0	%	32.7	%	38.8	%
Japan		63.3		78.6		133.3	35.5		36.5		37.5
Asia		41.8		39.5		51.7	23.4		18.4		14.6
Europe		18.0		26.8		32.5	10.1		12.4		9.1

Total net sales	$	178.4	$	215.3	$	355.5	100.0	%	100.0	%	100.0	%

	Net Sales Change in US Dollars				Net Sales Change in Local Currencies
	2002		2001		2002		2001
North America	(21.4	)%	(49.0	)%	(21.4	)%	(49.0	)%
Japan	(19.5	)	(41.0	)	(17.3	)	(33.8	)
Asia	5.8		(23.6	)	0.7		(18.0	)
Europe	(32.8	)	(17.5	)	(38.9	)	(21.1	)

Total net sales	(17.1	)%	(39.4	)%

	Payments Due by Period
	Total		Less than 1 Year		1-3 Years		4-5 Years		After 5 Years
	(In millions)
Operating leases	$	51.3	$	8.0	$	21.3	$	7.3	$	14.7

Total commitments	$	51.3	$	8.0	$	21.3	$	7.3	$	14.7

Consolidated and Combined Statements of Operations for the years ended December 31, 2002, 2001 and 2000		F-2
Consolidated and Combined Balance Sheets at December 31, 2002 and 2001		F-3
Consolidated and Combined Statements of Shareholders’ Equity for the years ended December 31, 2002, 2001 and 2000		F-4
Consolidated and Combined Statements of Cash Flows for the years ended December 31, 2002, 2001 and 2000		F-5
Notes to Consolidated and Combined Financial Statements		F-6
Report of Independent Accountants		F-32
Quarterly Results (Unaudited)		F-33
Financial Statement Schedule for the years ended December 31, 2002, 2001 and 2000		F-34

Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))⁽²⁾
	(a)	(b)		(c)
Equity compensation plans approved by security holders⁽¹⁾	8,013,577	$	9.97	1,231,102

Equity compensation plans not approved by security holders	N/A		N/A	N/A

Total	8,013,577	$	9.97	1,231,102

Reg. S-K Item 601(b) Reference	Document Incorporated	Referenced Document on file with the Commission

(2)	Form of Master Separation and Distribution Agreement	Exhibit 2.1 to Form S-1 Registration Statement (No. 333-57182)

	Form of General Assignment and Assumption Agreement	Exhibit 2.2 to Form S-1 Registration Statement (No. 333-57182)

(3)	Restated Certificate of Incorporation of Mykrolis Corporation	Exhibit 3.1 to Form S-1 Registration Statement (No. 333-57182)

	Amended and Restated By-laws of Mykrolis Corporation	Exhibit 3.2 to Form S-1 Registration Statement (No. 333-57182)

	Form of certificate representing shares of Common Stock, $.01 par value per share	Exhibit 3.3 to Form S-1 Registration Statement (No. 333-57182)

	Form of Common Stock Rights Agreement	Exhibit 1 to Form 8-K Current Report, filed December 10, 2001 [Commission File No. 001-1611]

	Form of Common Stock Purchase Right Certificate (included as Annex I to the Form of Common Rights Agreement)	Exhibit 2 to Form 8-K Current Report, filed December 10, 2001 [Commission File No. 001-1611]

Reg. S-K Item 601(b) Reference		Documents Filed Herewith

(10)		Standard Form of Agreements Between Owner and Design/Builder, effective as of January 15, 2002, between registrant and SPEC Process Engineering & Construction, as Design/Builder

		Supplemental Executive Retirement Plan for Key Salaried Employees of Mykrolis Corporation*

		Mykrolis Corporation 2002 Deferred Compensation Plan for Senior Management*

		2001 Non-Employee Director Stock Option Plan (As Amended October 1, 2002) *

(21)		Subsidiaries of Mykrolis Corporation

(24)		Power of Attorney

(99)		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

	MYKROLIS CORPORATION

Dated: March 13, 2003	By	/s/ C. WILLIAM ZADEL
		C. William Zadel Chairman and Chief Executive Officer

Signature	Title	Date

/s/ C. WILLIAM ZADEL	Chairman, Chief Executive Officer, and Director	March 13, 2003
C. William Zadel	Chairman, Chief Executive Officer, and Director	March 13, 2003

/s/ BERTRAND LOY	Vice President, Treasurer and Chief Financial Officer	March 13, 2003
Bertrand Loy	Vice President, Treasurer and Chief Financial Officer	March 13, 2003

/s/ ROBERT HAMMOND	Corporate Controller and Chief Accounting Officer	March 13, 2003
Robert Hammond	Corporate Controller and Chief Accounting Officer	March 13, 2003

RICHARD A. AURELIO*	Director	March 13, 2003
Richard A. Aurelio

MICHAEL A. BRADLEY*	Director	March 13, 2003
Michael A. Bradley

ROBERT E. CALDWELL*	Director	March 13, 2003
Robert E. Caldwell

MICHAEL P.C. CARNS*	Director	March 13, 2003
Michael P.C. Carns

DANIEL W. CHRISTMAN*	Director	March 13, 2003
Daniel W. Christman

THOMAS O. PYLE*	Director	March 13, 2003
Thomas O. Pyle

*By /s/ PETER W. WALCOTT
Peter W. Walcott, Attorney-in-Fact

	Common Shares			Additional Paid-In Capital			Shareholder’s Net Investment			Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total Shareholders’ Equity			Comprehensive Income (Loss)
	Shares	Amount		Additional Paid-In Capital			Shareholder’s Net Investment			Accumulated Deficit			Accumulated Other Comprehensive Income (Loss)			Total Shareholders’ Equity			Comprehensive Income (Loss)
Balance December 31, 1999			—		—			193,400			—			4,258			197,658
Net change in unearned compensation			—		—			1,107			—			—			1,107
Net transfers from Millipore Corporation			—		—			21,854			—			—			21,854
Comprehensive income :
Net income			—		—			37,371			—			—			37,371			37,371
Foreign currency translations			—		—			—			—			(11,501	)		(11,501	)		(11,501	)

Comprehensive income																				25,870

Balance December 31, 2000			—		—			253,732			—			(7,243	)		246,489
Net change in unearned compensation and Other stock-based compensation			—		503			3,240			—			—			3,743
Net transfers from (to) Millipore Corporation			—		1,850			(1,141	)		—			—			709
Payment of separation note to Millipore Corporation			—		(19,095	)		—			—			—			(19,095	)
Transfer to common stock and additional Paid-in capital	32,500		325		249,469			(249,794	)		—			—			—
Issuance of common stock – net of expenses	7,000		70		93,891			—			—			—			93,961
Comprehensive loss :
Net loss			—		—			(6,037	)		(61,590	)		—			(67,627	)		(67,627	)
Foreign currency translations			—		—			—			—			(14,633	)		(14,633	)		(14,633	)

Comprehensive loss																				(82,260	)

Balance December 31, 2001	39,500		395		326,618			—			(61,590	)		(21,876	)		243,547
Stock-based compensation			—		1,103			—			—			—			1,103
Net transfers to Millipore Corporation			—		(9,518	)		—			—			—			(9,518	)
Issuance of common stock-employee stock purchase plan and exercise of stock options	224		2		1,858			—			—			—			1,860
Comprehensive income (loss) :
Net loss			—		—			—			(31,761	)		—			(31,761	)		(31,761	)
Foreign currency translations			—		—			—			—			7,413			7,413			7,413

Comprehensive loss																			$	(24,348	)

Balance December 31, 2002.	39,724	$	397	$	320,061		$	—		$	(93,351	)	$	(14,463	)	$	212,644

Leasehold Improvements		Shorter of the life of the lease or the improvement
Buildings and Improvements		10-40 Years
Production and Other Equipment		3-15 Years
Software		3 years

	Year Ended December 31
	2002			2001			2000
Net income (loss), as reported	$	(31,761	)	$	(67,627	)	$	37,371
Deduct: Total stock based employee compensation expense determined under fair value based method for all awards, net of related tax effects		(15,770	)		(2,870	)		(1,587	)

Pro forma net income (loss)	$	(47,531	)	$	(70,497	)	$	35,784

Basic and diluted earnings (loss) per share:
As reported	$	(0.80	)	$	(1.92	)	$	1.15

Pro forma	$	(1.20	)	$	(2.00	)	$	1.10

	2002 Activity
	Balance December 31, 2001		2002 Expense		Cash Activity			Non-Cash Activity			Adjustments			Balance December 31, 2002
Workforce	$	3,813	$	1,708	$	(1,891	)	$	—		$	(1,638	)	$	1,992
Leasehold/Other		1,987		1,791		(1,627	)		—			1,638			3,789
Asset Impairment		—		1,683		—			(1,683	)		—			—

	$	5,800	$	5,182	$	(3,518	)	$	(1,683	)	$	—		$	5,781


	2001 Activity
	Balance December 31, 2000		2001 Expense		Cash Activity			Non-Cash Activity			Adjustments			Balance December 31, 2001
Workforce	$	—	$	13,755	$	(6,794	)	$	(3,148	)	$	—		$	3,813
Leasehold/Other		174		3,723		(475	)		(1,435	)		—			1,987
Asset Impairment		—		—		—			—			—			—

	$	174	$	17,478	$	(7,269	)	$	(4,583	)	$	—		$	5,800


	2000 Activity
	Balance December 31, 1999		2000 Expense		Cash Activity			Non-Cash Activity			Adjustments			Balance December 31, 2000
Workforce	$	320	$	—	$	—		$	—		$	(320	)	$	—
Leasehold/Other		174		—		—			—			—			174
Asset Impairment		—		—		—			—			—

	$	494	$	—	$	—		$	—		$	(320	)	$	174

Net book value of equipment before impairment	$	2,186
Impairment of book value		(971	)

Net book value of equipment after impairment	$	1,215
Net book value of equipment in service		(338	)
Net book value of equipment sold		(805	)

Assets held for sale at December 31, 2002	$	72

	Twelve months ended December 31
	2002			2001			2000
Net (loss) income	$	(31,761	)	$	(67,627	)	$	37,371
Add: Goodwill amortization		—			916			976

Adjusted net (loss) income	$	(31,761	)	$	(66,711	)	$	38,347

Basic and diluted (loss) income per share	$	(0.80	)	$	(1.92	)	$	1.15
Add: Goodwill amortization		—			0.03			0.03

Adjusted basic and diluted (loss) income per share	$	(0.80	)	$	(1.89	)	$	1.18

	As of December 31, 2002
	Gross carrying amount		Accumulated amortization
Patents	$	14,207	$	10,007
Unpatented technology		8,505		8,019
Trademarks / tradenames		2,906		2,892
Other		278		29

	Shares		Option Price		Weighted Average Exercise Price
Outstanding at January 1, 2001	—			—		—
Granted	4,374,171		$	9.10-$15.00	$	13.02
Exercised	—			—		—
Canceled	(211,720	)	$	9.10-$15.00	$	14.74

Outstanding at December 31, 2001	4,162,451		$	9.10-$15.00	$	12.93

Available for future grant at December 31, 2001	2,087,549
Exercisable at December 31, 2001	—
Outstanding at January 1, 2002	4,162,451		$	9.10-$15.00	$	12.93
Granted	4,728,507		$	5.20-$15.16	$	7.60
Exercised	(132,950	)	$	5.33-$15.00	$	9.77
Expired	(8,340	)	$	11.60-$15.00	$	12.75
Canceled	(736,091	)	$	5.33-$15.16	$	11.49

Outstanding at December 31, 2002	8,013,577		$	5.20-$15.16	$	9.97

Available for future grant at December 31, 2002	1,231,102
Exercisable at December 31, 2002	2,642,537

	Options Outstanding				Options Exercisable
Range of Exercise Prices	Outstanding	Weighted Average Remaining Life in Years	Weighted Average Exercise Price		Exercisable	Weighted Average Exercise Price
$5.20-$6.84	2,654,971	6.8	$	6.54	622,860	$	6.09
$8.48-$11.60	3,563,422	6.1	$	10.06	1,440,018	$	9.99
$12.80-$15.16	1,795,184	5.5	$	14.87	579,659	$	14.91

$5.20-$15.16	8,013,577	6.2	$	9.97	2,642,537	$	10.15

	Nihon Mykrolis Pension Plan						U.S. Post Retirement Benefits
	2002			2001			2002			2001
Change in benefit obligation:
Benefit obligation at beginning of year	$	8,778		$	11,747		$	1,031		$	1,444
Service cost		722			854			204			95
Interest cost		204			268			76			63
Amendments/Curtailment gain		—			—			—			(175	)
Actuarial loss (gain)		(1,198	)		(1,813	)		195			(396	)
Foreign exchange impact		953			(1,439	)		N/A			N/A
Benefits paid		(99	)		(839	)		—			—

Benefit obligation at end of year	$	9,360		$	8,778		$	1,506		$	1,031

Change in plan assets:
Fair value of plan assets at beginning of year	$	1,936		$	2,511			N/A			N/A
Actual return on plan assets		(110	)		(448	)		N/A			N/A
Company contributions		94			186			N/A			N/A
Foreign exchange impact		213			(313	)		N/A			N/A

Fair value of plan assets at end of year	$	2,133		$	1,936			N/A			N/A

Funded status	$	(7,227	)	$	(6,842	)	$	(1,506	)	$	(1,031	)
Unrecognized net loss (gain)		905			2,334			(176	)		(382	)

Accrued benefit cost	$	(6,322	)	$	(4,508	)	$	(1,682	)	$	(1,413	)

	1% Point Increase		1% Point Decrease
Effect on total of services and interest cost components	$	63	$	(52	)
Effect on postretirement benefit obligations		322		269

	Net Sales Year Ended December 31,
	2002		2001		2000
United States	$	55,344	$	70,393	$	138,055
Japan		63,323		78,562		133,348
Asia		41,803		39,494		51,684
Europe		17,980		26,825		32,453

Total	$	178,449	$	215,274	$	355,540

	Long-Lived Assets
	2002		2001
United States	$	74,619	$	72,730
Japan		18,013		16,662
Asia		1,125		865
Europe		481		585

Total	$	94,238	$	90,842

Purchased costs	Year ended December 31, 2002		Nine months ended December 31, 2001
Cost of sales	$	3,884	$	3,279
Selling, general and administrative		3,126		3,675
Research and development		642		1,082

Total	$	7,652	$	8,036

Costs provided	Year ended December 31, 2002		Nine months ended December 31, 2001
Cost of sales	$	870	$	1,186
Selling, general and administrative		880		222
Research and development		—		269

Total	$	1,750	$	1,677